

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 JAN 02 STN pricing information for 2008 now available  
NEWS 3 JAN 16 CAS patent coverage enhanced to include exemplified  
prophetic substances  
NEWS 4 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new  
custom IPC display formats  
NEWS 5 JAN 28 MARPAT searching enhanced  
NEWS 6 JAN 28 USGENE now provides USPTO sequence data within 3 days  
of publication  
NEWS 7 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment  
NEWS 8 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements  
NEWS 9 FEB 08 STN Express, Version 8.3, now available  
NEWS 10 FEB 20 PCI now available as a replacement to DPCI  
NEWS 11 FEB 25 IFIREF reloaded with enhancements  
NEWS 12 FEB 25 IMSPRODUCT reloaded with enhancements  
NEWS 13 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current  
U.S. National Patent Classification  
NEWS 14 MAR 31 IFICDB, IFIPAT, and IFIUDB enhanced with new custom  
IPC display formats  
NEWS 15 MAR 31 CAS REGISTRY enhanced with additional experimental  
spectra  
NEWS 16 MAR 31 CA/Caplus and CASREACT patent number format for U.S.  
applications updated  
NEWS 17 MAR 31 LPCI now available as a replacement to LDPCI  
NEWS 18 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements  
NEWS 19 APR 04 STN AnaVist, Version 1, to be discontinued  
NEWS 20 APR 15 WPIDS, WPINDEX, and WPIX enhanced with new  
predefined hit display formats  
NEWS 21 APR 28 EMBASE Controlled Term thesaurus enhanced  
NEWS 22 APR 28 IMSRESEARCH reloaded with enhancements  
NEWS 23 MAY 30 INPAFAMDB now available on STN for patent family  
searching  
NEWS 24 MAY 30 DGENE, PCTGEN, and USGENE enhanced with new homology  
sequence search option  
  
NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 12:14:54 ON 06 JUN 2008

=> eg

EG IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.  
For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (=>).

=> e tretinoin/cn

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

The EXPAND command is used to look at the index in a file  
which has an index. This file does not have an index.

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:15:14 ON 06 JUN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 5 JUN 2008 HIGHEST RN 1025900-65-5

DICTIONARY FILE UPDATES: 5 JUN 2008 HIGHEST RN 1025900-65-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> e tretinoin/cn

E1	1	TRETHYLENE/CN
E2	1	TRETIN M/CN
E3	1 -->	TRETINOIN/CN
E4	1	TRETINOIN TOCOFERIL/CN
E5	1	TRETINOIN TOCOFERIL MIXT. WITH 1A,25-DIHYDROXYVITAMIN D3/CN
E6	1	TRETOLITE AFTOL 21/CN
E7	1	TRETOQUINOL/CN
E8	1	TREUPEL/CN
E9	1	TREVALON/CN
E10	1	TREVALON C/CN
E11	1	TREVALON CLEAR/CN
E12	1	TREVALON HI/CN

=> s e3


L1 1 TRETINOIN/CN

=> d

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 302-79-4 REGISTRY  
ED Entered STN: 16 Nov 1984  
CN Retinoic acid (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN Retinoic acid, all-trans- (8CI)  
OTHER NAMES:  
CN (all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-  
nonatetraenoic acid  
CN  $\beta$ -Retinoic acid  
CN 2,4,6,8-Nonatetraenoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-  
1-yl)-, (all-E)-  
CN 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic  
acid  
CN Aberel  
CN AGN 100335  
CN Airol  
CN Aknoten  
CN all-(E)-Retinoic acid  
CN all-trans- $\beta$ -Retinoic acid  
CN all-trans-Retinoic acid  
CN all-trans-Tretinoin  
CN all-trans-Vitamin A acid  
CN ATRA  
CN Atragen  
CN Cordes Vas  
CN Dermaiol  
CN Epi-Aberel  
CN Eudyna  
CN NSC 122578  
CN NSC 122758  
CN Renova  
CN Retacnyl  
CN Retin A  
CN Ro 1-5488  
CN trans-Retinoic acid  
CN Tretin M  
CN Tretinoin  
CN Vesanoïd  
CN Vesnaroid  
CN Vitamin A acid  
CN Vitamin A acid, all-trans-  
CN Vitamin A1 acid, all-trans-  
FS STEREOSEARCH  
DR 7005-78-9, 56573-65-0, 187175-63-9  
MF C20 H28 O2  
CI COM  
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN\*,  
BIOSIS, BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS,  
CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DRUGU, EMBASE, HSDB\*,  
IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS,  
IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE, MRCK\*, MSDS-OHS, NAPRALERT, PHAR,  
PIRA, PROMT, PROUSDDR, PS, RTECS\*, SCISEARCH, SPECINFO, SYNTHLINE,  
TOXCENTER, TULSA, USAN, USPAT2, USPATFULL, USPATOLD  
(\*File contains numerically searchable property data)  
Other Sources: DSL\*\*, EINECS\*\*, TSCA\*\*, WHO

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

16347 REFERENCES IN FILE CA (1907 TO DATE)  
426 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
16376 REFERENCES IN FILE CAPLUS (1907 TO DATE)  
23 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> e misoprostol/cn

E13	1	MISOPROSTANOIC ACID/CN
E14	1	MISOPROSTIL/CN
E15	1 -->	MISOPROSTOL/CN
E16	1	MISOPROSTOL ACID/CN
E17	1	MISOPROSTOL FREE ACID/CN
E18	1	MISOPROSTOL-ASPIRIN MIXT./CN
E19	1	MISOPROSTOL-DICLOFENAC MIXT./CN
E20	1	MISOPROSTOL-FLURBIPROFEN MIXT./CN
E21	1	MISOPROSTOL-IBUPROFEN MIXT./CN
E22	1	MISOPROSTOL-NAPROXEN MIXT./CN
E23	1	MISOPROSTOL-PIROXICAM MIXT./CN
E24	1	MISP (DEINOPIS SPINOSA SILK GLANDS CLONE DS28 C-TERMINAL FRA GMENT)/CN

=> s e15

L2 1 MISOPROSTOL/CN

=> d

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 59122-46-2 REGISTRY  
ED Entered STN: 16 Nov 1984  
CN Prost-13-en-1-oic acid, 11,16-dihydroxy-16-methyl-9-oxo-, methyl ester,  
(11 $\alpha$ ,13E)-(±)- (CA INDEX NAME)

OTHER NAMES:

CN Cytotec  
CN Misogon  
CN Misoprostil  
CN Misoprostol  
CN SC 29333

FS STEREOSEARCH

DR 62015-39-8, 138284-96-5, 143913-16-0, 92999-98-9

MF C22 H38 O5

CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOSIS,


BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSICHEM, DDFU, DRUGU, EMBASE, HSDB\*, IMSCOSEARCH, IMSDRUGNEWS, IMPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE, MRCK\*, MSDS-OHS, PHAR, PROMT, PROUSDDR, PS, RTECS\*, SCISEARCH, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL, VETU

(\*File contains numerically searchable property data)

Other Sources: WHO

Relative stereochemistry.

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1563 REFERENCES IN FILE CA (1907 TO DATE)

16 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

1565 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> fil capl uspata

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

14.76

14.97

FILE 'CAPLUS' ENTERED AT 12:15:51 ON 06 JUN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 12:15:51 ON 06 JUN 2008

CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 12:15:51 ON 06 JUN 2008

CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 12:15:51 ON 06 JUN 2008

CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> fil capl uspata medl

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

4.98

19.95

FILE 'CAPLUS' ENTERED AT 12:15:56 ON 06 JUN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 12:15:56 ON 06 JUN 2008  
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 12:15:56 ON 06 JUN 2008  
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 12:15:56 ON 06 JUN 2008  
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 12:15:56 ON 06 JUN 2008

=> s l1  
L3 34133 L1

=> s l2  
L4 4236 L2

=> s l4 l3  
MISSING OPERATOR L4 L3  
The search profile that was entered contains terms or  
nested terms that are not separated by a logical operator.

=> s l4 and l3  
L5 36 L4 AND L3

=> s l5 and (ay<=2002 or py<=2002)  
'2002' NOT A VALID FIELD CODE  
L6 9 L5 AND (AY<=2002 OR PY<=2002)

=> d iabs ibib kwic str 1-9  
'STR' IS NOT A VALID FORMAT  
In a multifile environment, a format can only be used if it is valid  
in at least one of the files. Refer to file specific help messages  
or the STNGUIDE file for information on formats available in  
individual files.  
REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):end

=> d iabs ibib kwic hitstr 1-9

L6 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN  
ABSTRACT:

A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form. Tablets containing 10 mg sodium pravastatin and 1000 mg niacin were prepared The release of sodium pravastatin after 24 h was 67.7%, and the release of niacin after 1 h was 84.1%.

ACCESSION NUMBER: 2006:100738 CAPLUS  
DOCUMENT NUMBER: 144:198849  
TITLE: Novel dosage form comprising modified-release and  
immediate-release active ingredients

INVENTOR(S): Vaya, Navin; Karan, Rajesh Singh; Sadanand, Sunil;  
Gupta, Vinod Kumar  
PATENT ASSIGNEE(S): India  
SOURCE: U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S.  
Ser. No. 630,446.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060024365	A1	20060202	US 2005-134633	20050519
IN 2002MU00697	A	20040529	IN 2002-MU697	20020805 <--
IN 193042	A1	20040626		
IN 2002MU00699	A	20040529	IN 2002-MU699	20020805 <--
IN 2003MU00080	A	20050204	IN 2003-MU80	20030122
IN 2003MU00082	A	20050204	IN 2003-MU82	20030122
US 20040096499	A1	20040520	US 2003-630446	20030729

PRIORITY APPLN. INFO.:

			IN 2002-MU697	A	20020805
			IN 2002-MU699	A	20020805
			IN 2003-MU80	A	20030122
			IN 2003-MU82	A	20030122
			US 2003-630446	A2	20030729

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20060024365	A1	20060202	US 2005-134633	20050519
	IN 2002MU00697	A	20040529	IN 2002-MU697	20020805 <--
	IN 193042	A1	20040626		
	IN 2002MU00699	A	20040529	IN 2002-MU699	20020805 <--
	IN 2003MU00080	A	20050204	IN 2003-MU80	20030122
	IN 2003MU00082	A	20050204	IN 2003-MU82	20030122
	US 20040096499	A1	20040520	US 2003-630446	20030729
IT	85-79-0, Dibucaine	86-13-5, Benztropine	86-34-0, Phensuximide		
	86-35-1, Ethotoin	86-42-0, Amodiaquine	87-08-1, Penicillin V		
	87-90-1, Symclosene	89-25-8, Edaravone	89-57-6, Mesalamine	90-01-7,	
	Salicyl alcohol	90-03-9, Mercufenol chloride	90-33-5, Hymecromone		
	90-86-8, Cinnamedrine	91-33-8, Benzthiazide	92-13-7, Pilocarpine		
	93-23-2, Lauryl isoquinolinium bromide	94-09-7, Benzocaine	94-12-2,		
	Risocaine	94-14-4, Isobutamben	94-20-2, Chloropropamide	94-24-6,	
	Tetracaine	94-25-7, Butamben	94-36-0, Benzoyl peroxide, biological		
	studies	95-25-0, Chlorzoxazone	96-82-2	96-83-3, Iopanoic acid	
	97-24-5, Fenticlor	97-53-0, Eugenol	97-77-8, Disulfiram	98-72-6,	
	Nitarson	98-96-4, Pyrazinamide	99-66-1, Valproic acid	99-79-6,	
	Iophendylate	100-33-4, Pentamidine	100-55-0, Nicotiny alcohol		
	100-97-0, Methenamine, biological studies	101-26-8, Pyridostigmine			
	bromide	101-31-5, Hyoscyamine	101-40-6, Propylhexedrine	102-71-6,	
	Trolamine, biological studies	102-76-1, Triacetin	103-90-2,		
	Paracetamol	104-31-4, Benzonatate	106-48-9	108-46-3, Resorcinol,	
	biological studies	110-85-0, Piperazine, biological studies	112-24-3,		
	Trientine	112-38-9, Undecylenic acid	112-72-1, 1-Tetradecanol		
	112-92-5, Stearyl [alcohol;]	113-18-8, Ethchlorvynol	113-52-0,		
	Imipramine hydrochloride	113-59-7, Chlorprothixene	113-79-1D,		
	Argipressin, hcompds. with tannate	113-92-8, Chlorpheniramine maleate			
	113-98-4, Penicillingpotassium	114-07-8, Erythromycin	114-49-8,		
	Scopolamine hydrobromide	114-70-5, Sodium phenylacetate	114-80-7,		
	Neostigmine bromide	114-85-2, Bethanidine sulfate	114-86-3, Phenformin		

114-90-9, Obidoxime chloride 115-02-6, Azaserine 115-38-8, Mephobarbital 116-38-1, Edrophonium chloride 117-96-4, Diatrizoic acid 118-68-3, Etryptamine acetate 120-29-6D, Tropine, esters 120-97-8, Dichlorphenamide 121-19-7, Roxarsone 121-54-0, Benzethonium chloride 121-81-3, Nitromide 122-09-8, Phentermine 122-16-7, Sulfantran 122-18-9, Cetalkonium chloride 122-32-7D, Triolein, iodo derivs., iodine-125 and iodine 131 122-79-2, Phenylacetate 123-03-5, Cetylpyridinium chloride 123-63-7, Paraldehyde 123-99-9, Azelaic acid, biological studies 124-07-2, Octanoic acid, biological studies 124-43-6, Carbamide peroxide 124-72-1, Teflurane 124-94-7, Triamcinolone 125-33-7, Primidone 125-40-6, Butabarbital 125-45-1, Azetepa 125-71-3, Dextromethorphan 125-72-4, Levorphanol tartrate 126-07-8, Griseofulvin 126-22-7, Butonate 126-27-2, Oxethazaine 127-07-1, Hydroxyurea 127-33-3, Demeclocycline 127-48-0, Trimethadione 127-69-5, Sulfisoxazole 127-71-9, Sulfabenzamide 127-77-5, Sulfabenz 127-79-7, Sulfamerazine 128-13-2, Ursodiol 128-62-1, Noscaphine 129-06-6, Coumadin 129-20-4, Oxyphebutazone 129-49-7, Methysergide maleate 129-51-1, Ergonovine maleate 129-74-8, Bucizine hydrochloride 130-16-5, Cloxyquin 130-26-7, Clotioquinol 130-81-4, Quindonium bromide 131-49-7, Diatrizoate meglumine 132-17-2, Benztropine mesylate 132-35-4, Proxazole citrate 132-65-0, Dibenzothioephene 132-69-4, Benzydamine hydrochloride 132-92-3, Methicillin sodium 132-98-9, Penicillin potassium 133-11-9, Phenyl aminosalicylate 133-58-4, Nitromersol 133-67-5, Trichlormethiazide 134-80-5, Diethylpropion hydrochloride 135-07-9, Methyclothiazide 135-09-1, Hydroflumethiazide 136-40-3, Phenazopyridine hydrochloride 136-77-6, Hexylresorcinol 137-26-8, Thiram 137-53-1, Dextrothyroxine sodium 137-58-6, Lidocaine 138-39-6, Mafenide 143-67-9, Vinblastine sulfate 143-71-5, Hydrocodone bitartrate 144-14-9, Anileridine 144-80-9, Sulfacetamide 144-82-1, Sulfamethizole 145-63-1, Suramin 146-22-5, Nitrazepam 146-54-3, Triflupromazine 147-85-3, Proline, biological studies 147-94-4, Cytarabine 148-79-8, Thiabendazole 148-82-3, Melfalan 149-32-6, Erythritol 151-67-7, Halothane 152-11-4, Verapamil hydrochloride 152-43-2, Quinestrol 152-47-6, Sulfalene 152-58-9, Cortodoxone 152-97-6, Fluocortolone 153-87-7, Oxypertine 154-21-2, Lincomycin 154-41-6, Phenylpropanolamine hydrochloride 154-42-7, Thioguanine 154-68-7, Antazoline phosphate 154-69-8, Tripeleminamine hydrochloride 154-93-8, Carmustine 156-51-4, Phenelzine sulfate 271-95-4, 1,2-Benzisoxazole 297-76-7, Ethynodiol diacetate 298-46-4, Carbamazepine 298-57-7, Cinnarizine 298-59-9, Methylphenidate hydrochloride 299-39-8, Sparteine sulfate 299-42-3, Ephedrine 302-22-7, Chlormadinone acetate 302-49-8, Urethra 302-79-4, Tretinoin 303-53-7, Cyclobenzaprine 304-20-1, Hydralazine hydrochloride 304-55-2, Succimer 304-84-7, Ethamivan 305-03-3, Chlorambucil 306-07-0, Pargyline hydrochloride 306-21-8, Hydroxyamphetamine hydrobromide 309-36-4, Methohexital sodium 314-19-2, Apomorphine hydrochloride 315-80-0, Dibenzepin hydrochloride 316-42-7, Emetine hydrochloride 317-52-2, Hexafluorenum bromide 318-98-9, Propranolol hydrochloride 319-89-1, Tetroquinone 320-67-2, Azacitidine 322-35-0, Benserazide 326-43-2, Phenylamidol hydrochloride 329-65-7, Racepinephrine 333-36-8, Flurothyl 338-98-7, Isoflupredone acetate 339-72-0, Levycloserine 340-57-8, Mecloqualone 345-78-8, Pseudoephedrine hydrochloride 346-18-9, Polythiazide 356-12-7, Fluocinonide 357-07-3, Oxymorphone hydrochloride 357-70-0, Galantamine 359-83-1, Pentazocine 361-37-5, Methysergide 362-29-8, Propiomazine 363-20-2, Tricetamide 363-24-6, Dinoprostone 364-62-5, Metoclopramide 364-98-7, Diazoxide 366-70-1, Procarbazine hydrochloride 378-44-9, Betamethasone 379-79-3, Ergotamine tartrate 382-67-2, Desoximetasone



389-08-2, Nalidixic acid 390-64-7, Prenylamine 396-01-0, Triamterene  
 404-82-0, Fenfluramine hydrochloride 404-86-4, Capsaicin 406-90-6,  
 Fluoxetine 423-55-2, Perflubron 424-89-5, Clomegestone acetate  
 426-13-1, Fluorometholone 434-05-9, Methenolone acetate 434-07-1,  
 Oxymetholone 435-97-2, Phenprocoumon 437-74-1, Xanthinol niacinate  
 439-14-5, Diazepam 440-17-5, Trifluoperazine hydrochloride 443-48-1,  
 Metronidazole 446-86-6, Azathioprine 451-71-8, Glyhexamide 459-86-9,  
 Mitoguanine 465-65-6, Naloxone 466-06-8, Proscillaridin 467-22-1,  
 Carbiphen hydrochloride 472-15-1, Betulinic acid 474-25-9, Chenodiol  
 474-58-8, Sitogluside 474-86-2, Equilin 476-70-0, Boldine 480-30-8,  
 Dichloroalphenazone 480-39-7, Pinocembrin 483-63-6, Crotamiton  
 486-56-6, Cotinine 486-66-8, Daidzein 501-75-7

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(novel dosage form comprising modified-release and immediate-release  
 active ingredients)

IT 55242-77-8, Triafungin 55268-75-2, Cefuroxime 55294-15-0, Muzolimine  
 55298-68-5, Neomycin palmitate 55453-87-7, Isoxepac 55560-96-8,  
 Tioxocortol pivalate 55694-87-6, Pentizidone sodium 55695-56-2,  
 Cloroperone hydrochloride 55721-11-4, Secalciferol 55774-33-9,  
 Azathioprine sodium 55779-18-5, Arprinocid 55837-27-9, Piretanide  
 55837-29-1, Tiropamide 55870-64-9, Pentisomicin 55881-07-7,  
 Miokamycin 55905-53-8, Clebopride 55981-09-4, Nitazoxanide  
 56030-54-7, Sufentanil 56049-88-8, Indacrinone 56079-80-2, Ropitoin  
 hydrochloride 56093-45-9, Selenium sulfide 56119-96-1, Furozole  
 56187-89-4, Ximoprofen 56208-01-6, Pifarnine 56211-40-6, Torasemide  
 56219-57-9, Arildone 56281-36-8, Motretinide 56290-94-9, Medroxoalol  
 56383-05-2, Lindotrine 56391-55-0, Octazamide 56391-57-2, Nettlelicin  
 sulfate 56420-45-2, Epirubicin 56430-99-0, Flumecinol 56470-64-5,  
 Anordrin 56605-16-4D, Spiromustine, di-Ph derivs. 56611-65-5,  
 Oxagrelate 56689-42-0, Repromicin 56689-44-2, Nitramisole  
 hydrochloride 56717-18-1, Isotiquimide 56741-95-8, Bropiramine  
 56784-39-5, Ozolinone 56796-20-4, Cefmetazole 56917-29-4, Fluretofen  
 56980-93-9, Celiprolol 56995-20-1, Flupirtine 57010-32-9, Tiapamil  
 hydrochloride 57041-67-5, Desflurane 57067-46-6, Isamoxole  
 57109-90-7, Clorazepate dipotassium 57149-07-2, Naftopidil 57166-13-9,  
 Napactadine hydrochloride 57248-88-1, Pamidronate disodium 57262-94-9,  
 Setiptiline 57285-09-3, Folliculostatine 57381-26-7, Irsogladine  
 57432-61-8, Methylegonovine maleate 57441-90-4, Nimvedone sodium  
 57540-79-1, Nisbuterol mesylate 57645-05-3, Sermetacin 57653-26-6,  
 Fenobam 57666-60-1, Nitrafudam hydrochloride 57726-65-5, Nufenoxole  
 57773-63-4, Triptorelin 57773-65-6, Deslorelin 57775-22-1, Etoposide  
 hydrochloride 57781-15-4, Halopredone 57801-81-7, Brotizolam  
 57808-65-8, Closantal 57982-78-2, Budipine 57998-68-2, Diaziquone  
 58019-50-4, Menabitan hydrochloride 58019-65-1, Nabazenil 58066-85-6,  
 Miltefosine 58152-03-7, Isepamicin 58167-78-5, Tandamine hydrochloride  
 58239-89-7, Moxazocine 58261-91-9, Mefenidil 58473-74-8, Cintromide  
 58493-49-5, Olvanil 58497-00-0, Procinonide 58503-79-0, Meobentine  
 sulfate 58524-83-7, Ciprocinnone 58525-82-9, Azatyrosine  
 58581-89-8, Aelastine 58712-69-9, Traxanox 58795-03-2, Apalcillin  
 sodium 58934-46-6, Lorcanine hydrochloride 58944-73-3, Sinefungin  
 58957-92-9, Idarubicin 58970-76-6, Ubenimex 59017-64-0, Ioxaglic acid  
 59018-13-2, Ioxaglate meglumine 59070-06-3, Ticarcillin cresyl sodium  
 59122-46-2, Misoprostol 59160-29-1, Lidofenin 59170-23-9,  
 Bevantolol 59179-95-2, Lorazepam 59227-89-3, Laurocapram 59263-76-2,  
 Meptazinol hydrochloride 59333-90-3, Exaprolol hydrochloride  
 59467-96-8, Midazolam hydrochloride 59497-39-1, Naflcort 59653-73-5,  
 Teroxirone 59703-84-3, Piperacillin sodium 59729-33-8, Citalopram  
 59733-86-7, Butikacin 59756-39-7, Enolicam sodium 59794-18-2,

Paulomycin 59803-98-4, Brimonidine 59804-37-4, Tenoxicam 59831-63-9,  
 Doconazole 59831-64-0, Milenperone 59831-65-1, Halopemide  
 59917-39-4, Vindesine sulfate 59937-28-9, Malotilate 59954-01-7,  
 Pamatolol sulfate 60019-19-4, Iotetric acid 60050-95-5, Sulfoxamine  
 60084-10-8, Tiazofurin 60086-22-8, Clopipazan mesylate 60135-22-0,  
 Flumoxonide 60142-96-3, Gabapentin 60166-93-0, Topamidol 60200-06-8,  
 Clorsulon 60207-31-0, Azaconazole 60209-20-3, Lycetamine 60282-87-3,  
 Gestodene 60325-46-4, Sulprostone 60398-23-4, Iodoamiloride  
 60400-92-2, Proxicromil 60525-15-7, Zimelidine hydrochloride  
 60560-33-0, Pinacidil 60569-19-9, Propiverine 60607-34-3, Oxatomeide  
 60607-35-4, Topterone 60628-96-8, Bifonazole 60653-25-0, Orpanoxin  
 60719-84-8, Amrinone 60719-85-9, Cipefadol succinate 60762-57-4,  
 Pirindole 60857-08-1, Prostratin 60925-61-3, Ceftoranide 60940-34-3,  
 Ebselen 60976-05-8 61036-62-2, Teicoplanin 61177-45-5, Clavulanate  
 potassium 61220-69-7, Tiopinac 61260-05-7, Prenalterol hydrochloride  
 61263-35-2, Meteneprost 61270-78-8, Cefonicid sodium 61318-91-0,  
 Sulconazole nitrate 61325-80-2, Flumezapine 61379-65-5, Rifapentine  
 61380-27-6, Carfentanil citrate 61380-41-4, Lofentanil oxalate  
 61413-54-5, Rolipram 61444-62-0, Nifluride 61477-94-9, Pirmenol  
 hydrochloride 61481-30-9, Dicranin 61484-39-7, Pareptide sulfate  
 61489-71-2, Menotropin 61570-90-9, Tioxidazole 61622-34-2, Cefotiam  
 61825-94-3, Oxalipatin 61849-14-7, Epoprostenol sodium 61869-08-7,  
 Paroxetine 62013-04-1, Dirithromycin 62087-72-3, Pentigetide  
 62134-34-3, Butopropine hydrochloride 62220-58-0, Bipenamol  
 hydrochloride 62265-68-3, Quinfamide 62304-98-7, Thymalfasin  
 62435-42-1, Perfosfomide 62488-57-7 62571-86-2, Captopril  
 62571-87-3, Minaxolone 62587-73-9, Cefsulodin 62613-82-5, Oxiracetam  
 62625-19-8, Pirogliride tartrate 62658-63-3, Bopindolol 62666-20-0,  
 Progabide 62732-44-9, Ipidacrine 62816-98-2, Ormaplatin 62851-43-8,  
 Zidometacin 62893-20-3, Cefoperazone sodium 62928-11-4, Iproplatin  
 62929-91-3, Procaterol hydrochloride 62973-76-6, Azanidazole  
 62973-77-7, Parconazole hydrochloride 62989-33-7, Saproterin  
 62996-74-1, Staurosporine 63119-27-7, Anitrazafen 63198-97-0, Viroxime  
 63204-23-9, Oxmetidine hydrochloride 63245-28-3, Etifenin 63251-39-8,  
 Sulfinalol hydrochloride 63269-31-8, Ciramadol 63358-49-6,  
 Aspoxicillin 63534-64-5, Iosulamide meglumine 63585-09-1, Foscarnet  
 sodium 63590-19-2, Balanol 63590-64-7, Terazosin 63612-50-0,  
 Nilutamide 63659-18-7, Betaxolol 63659-19-8, Betaxolol hydrochloride  
 63675-72-9, Nisoldipine 63774-77-6, Somatomedin B 63941-73-1, Iogluccol  
 63941-74-2, Ioglucomide 63950-06-1, Esorubicin hydrochloride  
 64019-93-8, Dipivefrin hydrochloride 64059-66-1, Cetaben sodium  
 64063-83-8, Picotrin diolamine 64092-48-4, Zomepirac sodium  
 64211-45-6, Oxiconazole 64221-86-9, Imipenem 64228-81-5, Atracurium  
 besylate 64318-79-2, Gemeprost 64379-93-7, Cinflumide 64420-40-2,  
 Etibendazole 64461-82-1, Tizanidine hydrochloride 64485-93-4,  
 Cefotaxime sodium 64706-54-3, Bepridil 64808-48-6, Lobenzarit sodium  
 64872-77-1, Butoconazole nitrate 64924-67-0, Halofuginone hydrobromide  
 64953-12-4, Moxalactam disodium 65009-35-0, Lidamide hydrochloride  
 65043-22-3, Indoloxazine hydrochloride 65052-63-3, Cefetamet  
 65057-90-1, Talisomycin 65093-40-5, Cytarabine ocfofate 65141-46-0,  
 Nicorandil 65222-35-7, Pazelliptine 65271-80-9, Mitoxantrone  
 65277-42-1, Ketoconazole 65322-72-7, Endralazine mesylate  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (novel dosage form comprising modified-release and immediate-release  
 active ingredients)


IT 302-79-4, Tretinoin 59122-46-2, Misoprostol  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (novel dosage form comprising modified-release and immediate-release

active ingredients)

RN 302-79-4 CAPLUS

CN Retinoic acid (CA INDEX NAME)

Double bond geometry as shown.




RN 59122-46-2 CAPLUS

CN Prost-13-en-1-oic acid, 11,16-dihydroxy-16-methyl-9-oxo-, methyl ester, (11 $\alpha$ ,13E)-(±)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



L6 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ABSTRACT:

Mol. connectivity has been applied to the search of math. models able to predict the carcinogenic and teratogenic activity of a wide group of structurally heterogeneous compds. Through the linear discriminant anal. and the diagrams of distribution of pharmacol. activity, the classification criteria that minimizes the percentage of error are established. The easiness and speed of the calcn. of the descriptors used in this work make the models developed useful in data bases containing a huge number of compds.

ACCESSION NUMBER: 2001:656048 CAPLUS

DOCUMENT NUMBER: 136:16468

TITLE: Search of a topological pattern to evaluate toxicity of heterogeneous compounds

AUTHOR(S): Garcia-Domenech, R.; De Julian-Ortiz, J. V.; Duarte, M. J.; Garcia-Torrecillas, J. M.; Anton-Fos, G. M.; Rios-Santamarina, I.; De Gregorio-Alapont, C.; Galvez, J.

CORPORATE SOURCE: Unidad de Investigacion de Diseno de Farmacos y Conectividad Molecular. Dpto de Quimica Fisica, Facultad de Farmacia, Unidad de Investigacion de Diseno de Farmacos y Conectividad Molecular. Dpto de Quimica Fisica, Facultad de Farmacia, Universidad de

SOURCE: Valencia, Valencia, 46100, Spain  
SAR and QSAR in Environmental Research (2001)  
, 12(1-2), 237-254  
CODEN: SQERED; ISSN: 1062-936X

PUBLISHER: Gordon & Breach Science Publishers

DOCUMENT TYPE: Journal

LANGUAGE: English

SO SAR and QSAR in Environmental Research (2001), 12(1-2), 237-254  
CODEN: SQERED; ISSN: 1062-936X

IT 50-00-0, Formaldehyde, biological studies 50-06-6, Phenobarbital, biological studies 50-18-0, Cyclophosphamide 50-28-2, Estradiol, biological studies 50-29-3, DDT, biological studies 50-32-8, Benzo[a]pyrene, biological studies 50-35-1, Thalidomide 50-47-5, Desipramine 50-48-6, Amitriptyline 50-53-3, Chlorpromazine, biological studies 50-55-5, Reserpine 50-59-7, Glucose, biological studies 51-06-9, Procainamide 51-41-2, Norepinephrine 51-43-4, Epinephrine 51-52-5, Propylthiouracil 51-61-6, Dopamine, biological studies 51-75-2, Mechlorethamine 51-79-6, Urethan 52-24-4, Triethylenethiophosphoramide 53-16-7, Estrone, biological studies 53-70-3, 1,2:5,6-Dibenzanthracene 53-86-1, Indomethacin 53-96-3, N-2-Fluorenylacetylacetamide 54-85-3, Isoniazide 55-18-5, N-Nitrosodimethylamine 56-23-5, Carbon tetrachloride, biological studies 56-53-1, Diethylstilbestrol 56-54-2, Quinidine 56-55-3, 1,2-Benzanthracene 56-75-7, Chloramphenicol 57-14-7, 1,1-Dimethylhydrazine 57-41-0, Phenytoin 57-42-1, Meperidine 57-53-4, Meprobamate 57-57-8,  $\beta$ -Propiolactone 57-63-6, Ethinyl estradiol 57-66-9, Probenecid 57-83-0, Progesterone, biological studies 58-08-2, Caffeine, biological studies 58-25-3, Chlordiazepoxide 58-39-9, Perphenazine 58-40-2, Promazine 58-55-9, Theophylline, biological studies 58-63-9, Inosine 58-74-2, Papaverine 58-89-9, Lindane 59-05-2, Methotrexate 59-89-2, N-Nitrosomorpholine 59-96-1, Phenoxymethylamine 59-99-4, Neostigmine 60-11-7, p-Dimethylaminoazobenzene 60-34-4, Methylhydrazine 60-51-5, Dimethoate 60-87-7, Promethazine 61-56-3, Sultiamine 61-68-7, Mefenamic acid 61-82-5, Amitrole 62-44-2, Phenacetin 62-56-6, Thiourea, biological studies 62-75-9, N-Nitrosodimethylamine 64-86-8, Colchicine 67-20-9, Nitrofurantoin 67-66-3, Chloroform, biological studies 67-72-1, Hexachloroethane 68-22-4, Norethindrone 68-26-8, Retinol 69-23-8, Fluphenazine 70-00-8, Trifluridine 70-25-7, N-Methyl-N'-nitro-N-nitrosoguanidine 71-43-2, Benzene, biological studies 72-33-3, Mestranol 72-43-5, Methoxychlor 73-24-5, Adenine, biological studies 73-48-3, Bendrofluazide 74-55-5, Ethambutol 74-79-3, Arginine, biological studies 74-83-9, Methylbromide, biological studies 74-87-3, Methyl chloride, biological studies 74-88-4, Methyl iodide, biological studies 75-01-4, Vinyl chloride, biological studies 75-09-2, Methylene chloride, biological studies 75-21-8, Ethylene oxide, biological studies 75-27-4, Bromodichloromethane 75-56-9, Propylene oxide, biological studies 76-75-5, Thiopental 77-36-1, Chlorthalidone 77-86-1, Trometamol 78-87-5, Propylene dichloride 79-00-5, 1,1,2-Trichloroethane 79-01-6, Trichloroethylene, biological studies 79-06-1, Acrylamide, biological studies 79-46-9, 2-Nitropropane 79-83-4, Pantothenic acid 81-07-2, Saccharin 82-95-1, Buclizine 84-22-0, Tetrahydrozoline 84-96-8, Alimemazine 85-41-6, Phthalimide 85-84-7, Yellow AB 86-54-4, Hydralazine 87-08-1, Penicillin V 88-06-2, 2,4,6-Trichlorophenol 90-94-8, Michler's Ketone 91-59-8, 2-Naphthylamine 91-81-6, Tripelennamine 91-94-1, 3,3'-Dichlorobenzidine 92-67-1, p-Biphenylamine 92-87-5, Benzidine 94-59-7, Safrole 94-78-0, Phenazopyridine 95-06-7, Sulfallate

95-53-4, o-Aminotoluene, biological studies 96-12-8,  
 Dibromochloropropane 96-45-7, Ethylene thiourea 97-56-3,  
 o-Aminoazotoluene 97-77-8, Disulfiram 98-07-7, Benzotrichloride  
 100-63-0, Phenylhydrazine 101-14-4, 4,4'-Methylenebis(2-chloroaniline)  
 101-61-1, Michler's Base 103-90-2, Acetaminophen 106-89-8,  
 Epichlorohydrin, biological studies 106-93-4, Ethylene dibromide  
 106-99-0, 1,3-Butadiene, biological studies 107-06-2, Ethylene  
 dichloride, biological studies 107-13-1, Acrylonitrile, biological  
 studies 107-30-2, Chloromethyl methyl ether 109-86-4, Methyl  
 cellosolve 113-92-8 114-26-1, Propoxur 115-67-3, Paramethadione  
 117-81-7, Bis(2-ethylhexyl)phthalate 117-89-5, Trifluoperazine  
 118-42-3, Hydroxychloroquine 118-74-1, Hexachlorobenzene 119-93-7,  
 o-Tolidine 123-91-1, Dioxane, biological studies 125-71-3,  
 Dextromethorphan 125-84-8, Aminogluthetimide 126-72-7,  
 Tris-(2,3-dibromopropyl)phosphate 126-85-2, Mechlorethamine oxide  
 127-18-4, Tetrachloroethylene, biological studies 127-48-0,  
 Trimethadione 131-79-3, Yellow OB 134-32-7, 1-Naphthylamine  
 135-20-6, Cupferron 137-58-6, Lidocaine 139-13-9, Nitrioltriacetic  
 acid 140-57-8, Aramite 140-88-5, Ethyl acrylate 143-50-0,  
 Chlordecone 148-82-3, Melphalan 151-56-4, Ethylenimine, biological  
 studies 153-61-7, Cephalothin 154-93-8, Carmustine 155-97-5,  
 Pyridostigmine 156-10-5, p-Nitrosodiphenylamine 298-46-4,  
 Carbamazepine 298-81-7, Methoxsalen 302-01-2, Hydrazine, biological  
 studies 302-79-4, Retinoic acid 303-47-9, Ochratoxin A  
 303-53-7, Cyclobenzaprine 305-03-3, Chlorambucil 312-48-1, Edrophonium  
 315-30-0, Allopurinol 316-81-4, Thioproperazine 359-83-1, Pentazocine  
 364-62-5, Metoclopramide 390-28-3, Methoxamine 395-28-8, Isoxsuprine  
 434-07-1, Oxymetholone 438-60-8, Protriptyline 443-48-1, Metronidazole  
 446-86-6, Azathioprine 456-59-7, Cycandelate 465-65-6, Naloxone  
 469-21-6, Doxylamine 469-83-0, Cafestol 479-92-5, Propyphenazone  
 484-20-8, Bergapten 494-03-1, Chlornaphazine 500-92-5, Proguanil  
 505-60-2, Mustard gas 509-14-8, Tetranitromethane 513-37-1,  
 1-Chloro-2-methyl-1-propene 519-37-9, Etofylline 525-66-6, Propranolol  
 532-03-6, Methocarbamol 536-33-4, Ethionamide 542-75-6,  
 1,3-Dichloropropene 542-88-1 548-73-2, Droperidol 555-30-6,  
 Methylidopa 556-52-5, Glycidol 563-47-3, 3-Chloro-2-methyl-1-propene  
 564-00-1, Erythritol anhydride 569-65-3, Meclizine 584-84-9, Toluene  
 2,4-diisocyanate 585-86-4, Lactitol 599-79-1, Sulfasalazine  
 615-05-4, 2,4-Diaminoanisole 616-91-1, Acetylcysteine 642-72-8,  
 Benzydamine 671-16-9, Procarbazine 709-55-7, Etilefrin 721-50-6,  
 Prilocaine 739-71-9, Trimipramine 835-31-4, Naphazoline 930-55-2,  
 N-Nitrosopyrrolidine 959-14-8, Oxolamine 965-52-6, Nifuroxazide  
 1088-11-5, Nordazepam 1110-40-3, Cortivazol 1116-54-7,  
 N-Nitrosodiethanolamine 1195-16-0, Citilone 1491-59-4, Oxymetazoline  
 1563-66-2, Carbofuran 1668-19-5, Doxepin 1695-77-8, Spectinomycin  
 1746-01-6, TCDD 1836-75-5, Nitrofen 1977-10-2, Loxapine 2058-52-8,  
 Clothiapine 2062-78-4, Pimozide 2104-64-5, EPN 2363-58-8,  
 Epitostanol 2385-85-5, Mirex 2395-99-5, p-Nitrophenyl 2622-26-6,  
 Pericyazine 3116-76-5, Dicloxacillin 3703-79-5, Bamethan 3736-08-1,  
 Fenetylline 3737-09-5, Disopyramide 3930-20-9, Sotalol 4205-90-7,  
 Clonidine

RL: ADV (Adverse effect, including toxicity); PRP (Properties); BIOL  
 (Biological study)

(search of topol. pattern to evaluate toxicity of heterogeneous  
 compds.)

IT 4267-05-4, Teclothiazide 4342-03-4, Dacarbazine 4419-39-0,  
 Beclomethasone 4618-18-2, Lactulose 4740-78-7, Glycerol formal  
 4759-48-2, Isotretinoin 5464-28-8, Glycerol formal 5588-16-9,

Althiazide 6452-71-7, Oxprenolol 6533-00-2, Norgestrel 6740-88-1,  
 Ketamine 7261-97-4, Dantrolene 7491-74-9, Piracetam 7683-59-2,  
 Isoproterenol 7706-67-4, Dimercrotic acid 10262-69-8, Maprotiline  
 13010-47-4, Lomustine 13392-18-2, Fenoterol 13655-52-2, Alprenolol  
 14008-44-7, Metopimazine 14222-60-7, Protionamide 14860-49-2,  
 Clobutinol 14901-08-7, Cycasin 15301-69-6, Flavoxate 15307-86-5,  
 Diclofenac 15687-27-1, Ibuprofen 16110-51-3, Cromoglicic acid  
 17692-31-8, Dropropizine 18323-44-9, Clindamycin 18559-94-9, Albuterol  
 18883-66-4, Streptozocin 19216-56-9, Prazosin 19794-93-5, Trazodone  
 21829-25-4, Nifedipine 22071-15-4, Ketoprofen 22204-53-1, Naproxen  
 22916-47-8, Miconazole 23214-92-8, Doxorubicin 23593-75-1,  
 Clotrimazole 24219-97-4, Mianserin 25013-16-5, Butylated  
 hydroxyanisole 25046-79-1, Glisoxepid 25523-97-1, Dexchlorpheniramine  
 26652-09-5, Ritodrine 26787-78-0, Amoxicillin 26839-75-8, Timolol  
 26973-24-0, Ceftezole 28395-03-1, Bumetanide 29122-68-7, Atenolol  
 30748-29-9D, Prenazone, Ph derivative 31828-71-4, Mexiletine 32059-15-7,  
 Guanazodine 33419-42-0, Etoposide 34368-04-2, Dobutamine 34661-75-1,  
 Urapidil 36322-90-4, Piroxicam 36791-04-5, Ribavirin 36894-69-6,  
 Labetalol 37517-30-9, Acebutolol 38194-50-2, Sulindac 39515-40-7,  
 Cyphenothrin 42200-33-9, Nadolol 50935-04-1, Carubicin 51384-51-1,  
 Metoprolol 51781-06-7, Carteolol 53902-12-8, Tranilast 54063-54-6,  
 Reproterol 54350-48-0, Etretinate 54739-18-3, Fluvoxamine  
 54910-89-3, Fluoxetine 55079-83-9, Acitretin 56211-40-6, Torasemide  
 56980-93-9, Celiprolol 58001-44-8, Clavulanic acid 59122-46-2,  
 Misoprostol 59338-93-1, Alizapride 60205-81-4, Ipratropium  
 60576-13-8, Picketoprofen 60607-34-3, Oxatamide 60719-84-8, Amrinone  
 63659-18-7, Betaxolol 66085-59-4, Nimodipine 66195-31-1, Ibopamine  
 66357-35-5, Ranitidine 66564-14-5, Cinitapride 66722-44-9, Bisoprolol  
 68302-57-8, Amlexanox 69049-73-6, Nedocromil 71195-58-9, Alfentanil  
 72332-33-3, Procaterol 73384-59-5, Ceftriaxone 73590-58-6, Omeprazole  
 74103-06-3, Ketorolac 78415-72-2, Milrinone 81098-60-4, Cisapride  
 81801-12-9, Xamoterol 99593-25-6, Rilmazafone 106685-40-9, Adapalene  
 109889-09-0, Granisetron


RL: ADV (Adverse effect, including toxicity); PRP (Properties); BIOL  
 (Biological study)  
 (search of topol. pattern to evaluate toxicity of heterogeneous  
 compds.)

IT 302-79-4, Retinoic acid 59122-46-2, Misoprostol  
 RL: ADV (Adverse effect, including toxicity); PRP (Properties); BIOL  
 (Biological study)  
 (search of topol. pattern to evaluate toxicity of heterogeneous  
 compds.)

RN 302-79-4 CAPLUS

CN Retinoic acid (CA INDEX NAME)

Double bond geometry as shown.




RN 59122-46-2 CAPLUS

CN Prost-13-en-1-oic acid, 11,16-dihydroxy-16-methyl-9-oxo-, methyl ester,

(11 $\alpha$ ,13E)-(±)- (CA INDEX NAME)

Relative stereochemistry.  
Double bond geometry as shown.



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2008 ACS on SIN

ABSTRACT:

The invention discloses methods, gene databases, gene arrays, protein arrays, and devices that may be used to determine the hypersensitivity of individuals to a given agent, such as drug or other chemical, in order to prevent toxic side effects. In one embodiment, methods of identifying hypersensitivity in a subject by obtaining a gene expression profile of multiple genes associated with hypersensitivity of the subject suspected to be hypersensitive, and identifying in the gene expression profile of the subject a pattern of gene expression of the genes associated with hypersensitivity are disclosed. The gene expression profile of the subject may be compared with the gene expression profile of a normal individual and a hypersensitive individual. The gene expression profile of the subject that is obtained may comprise a profile of levels of mRNA or cDNA. The gene expression profile may be obtained by using an array of nucleic acid probes for the plurality of genes associated with hypersensitivity. The expression of the genes predetd. to be associated with hypersensitivity is directly related to prevention or repair of toxic damage at the tissue, organ or system level. Gene databases arrays and apparatus useful for identifying hypersensitivity in a subject are also disclosed.

ACCESSION NUMBER: 2001:338762 CAPLUS  
DOCUMENT NUMBER: 134:362292  
TITLE: Methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile  
INVENTOR(S): Farr, Spencer  
PATENT ASSIGNEE(S): Phase-1 Molecular Toxicology, USA  
SOURCE: PCT Int. Appl., 222 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032928	A2	20010510	WO 2000-US30474	20001103 <--
WO 2001032928	A3	20020725		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,  
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,  
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,  
YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-165398P P 19991105  
US 2000-196571P P 20000411

PI	WO 2001032928 A2	<u>20010510</u>		
	PATENT NO.	KIND	DATE	APPLICATION NO.
	-----	----	-----	-----
PI	WO 2001032928	A2	20010510	WO 2000-US30474
	WO 2001032928	A3	20020725	20001103 <--
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW		
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
IT	50-02-2, Dexamethasone	50-06-6, Phenobarbital, biological studies		
	50-18-0, Cyclophosphamide	50-23-7, Hydrocortisone	50-24-8,	
	Prednisolone	50-28-2, Estradiol, biological studies	50-44-2,	
	6-Thiopurine	50-48-6, Amitriptyline	50-55-5, Reserpine	50-76-0,
	Actinomycin D	50-78-2, Aspirin	51-06-9, Procainamide	51-21-8,
	Fluorouracil	51-34-3, Scopolamine	51-48-9, Levothyroxine, biological studies	
	51-49-0, Dextrothyroxine	51-55-8, Atropine, biological studies		
	51-75-2, Mechlorethamine	52-01-7, Spironolactone	52-53-9, Verapamil	
	52-67-5, Penicillamine	52-86-8, Haloperidol	53-03-2, Prednisone	
	53-06-5, Cortisone	53-19-0, Mitotane	53-33-8, Paramethasone	53-86-1,
	Indomethacin	54-05-7, Chloroquine	54-11-5, Nicotine	54-31-9,
	Furosemide	54-36-4, Metyrapone	54-85-3, Isoniazid	55-63-0,
	Nitroglycerin	55-65-2, Guanethidine	55-98-1, Busulfan	56-54-2,
	Quinidine	56-75-7, Chloramphenicol	57-22-7, Vincristine	57-41-0,
	Phenytol	57-53-4, Meprobamate	57-63-6, Ethinyl estradiol	57-66-9,
	Probenecid	57-83-0, Progesterin, biological studies	57-96-5,	
	Sulfapyrazone	58-05-9, Leucovorin	58-14-0, Pyrimethamine	58-32-2,
	Dipyridamole	58-39-9, Perphenazine	58-54-8, Ethacrynic acid	58-55-9,
	Theophylline, biological studies	58-61-7, Adenosine, biological studies		
	58-74-2, Papaverine	58-93-5, Hydrochlorothiazide	58-94-6, Thiazide	
	59-05-2, Methotrexate	59-42-7, Phenylephrine	59-43-8, Thiamine,	
	biological studies	59-92-7, Levodopa, biological studies	59-99-4,	
	Neostigmine	60-40-2, Mecamylamine	60-54-8, Tetracycline	60-79-7,
	Ergonovine	60-87-7, Promethazine	61-32-5, Methicillin	61-72-3,
	Cloxacillin	64-75-5, Tetracycline hydrochloride	64-77-7, Tolbutamide	
	64-86-8, Colchicine	65-23-6, Pyridoxine	66-79-5, Oxacillin	66-97-7,
	Psoralen	67-20-9, Nitrofurantoin	67-45-8, Furazolidone	67-68-5,
	Dimethyl sulfoxide, biological studies	68-22-4D, Norethindrone, mixture with ethinyl estradiol	68-41-7, Cycloserine	68-88-2, Hydroxyzine
	69-53-4, Ampicillin	69-72-7, biological studies	69-89-6, Xanthine	
	73-24-5, 6-Aminopurine, biological studies	73-31-4, Melatonin	76-42-6,	
	Oxycodone	76-57-3, Codeine	77-09-8, Phenolphthalein	77-19-0,
	Dicyclomine	77-36-1, Chlorthalidone	78-44-4, Carisoprodol	80-08-0,
	Dapsone	81-23-2, Dehydrocholic acid	81-81-2, Warfarin	82-92-8,



Cyclizine 82-95-1, Buclizine 83-43-2, Methylprednisolone 83-73-8,  
 Iodoquinol 83-89-6, Quinacrine 83-98-7, Orphenadrine 86-54-4,  
 Hydralazine 89-57-6, Mesalamine 90-34-6, Primaquine 90-82-4,  
 Pseudoephedrine 91-64-5, Coumarin 92-13-7, Pilocarpine 92-84-2,  
 Phenothiazine 93-14-1, Guaifenesin 94-20-2, Chlorpropamide 94-36-0,  
 Benzoyl peroxide, biological studies 94-78-0, Phenazopyridine 95-25-0,  
 Chlorzoxazone 96-64-0, Soman 97-77-8, Disulfiram 99-66-1, Valproic  
 acid 100-33-4, Pentamidine 100-97-0, Methenamine, biological studies  
 101-31-5, Hyoscyamine 103-90-2, Acetaminophen 113-18-8, Ethchlorvynol  
 113-42-8, Methylergonovine 113-45-1, Methylphenidate 114-07-8,  
 Erythromycin 114-86-3, Phenformin 118-42-3, Hydroxychloroquine  
 122-09-8, Phentermine 123-56-8, Succinimide 123-63-7, Paraldehyde  
 124-94-7, Triamcinolone 125-29-1, Hydrocodone 125-33-7, Primidone  
 125-64-4, Methpyrrolone 125-71-3, Dextromethorphan 125-84-8,  
 Aminoglutethimide 126-07-8, Griseofulvin 126-52-3, Ethinamate  
 127-07-1, Hydroxyurea 127-69-5, Sulfisoxazole 128-13-2, Ursodiol  
 130-95-0, Quinine 132-17-2, Benzotropine 133-10-8, Sodium  
 p-aminosalicylate 137-58-6, Lidocaine 138-56-7, Trimethobenzamide  
 144-11-6, Trihexyphenidyl 147-52-4, Nafcillin 147-94-4, AraC  
 148-82-3, Melphalan 154-21-2, Lincomycin 154-42-7, Thioquanine  
 154-93-8, Carmustine 155-97-5, Pyridostigmine 298-46-4,  
 5H-Dibenz[b,f]azepine-5-carboxamide 298-50-0, Propantheline 299-42-3,  
 Ephedrine 300-62-9D, Amphetamine, mixed 300-62-9D, Amphetamine, mixed  
 salts 302-17-0, Chloral hydrate 302-79-4, Tretinoin  
 303-53-7, Cyclobenzaprine 305-03-3, Chlorambucil 315-30-0, Allopurinol  
 321-64-2, Tacrine 346-18-9, Polythiazide 361-37-5, Methysergide  
 363-24-6, Dinoprostone 364-62-5, Metoclopramide 378-44-9,  
 Betamethasone 389-08-2, Nalidixic acid 395-28-8, Isoxsuprine  
 439-14-5, Diazepam 443-48-1, Metronidazole 446-86-6, Azathioprine  
 456-59-7, Cyclandelate 461-72-3, Hydantoin 463-04-7, Amyl nitrite  
 469-62-5, Propoxyphene 474-25-9, Chenodiol 480-30-8,  
 Dichloralphenazone 484-23-1, Dihydralazine 503-01-5, Isometheptene  
 512-15-2, Cyclopentolate 520-85-4, Medroxyprogesterone 525-66-6,  
 Propanolol 526-36-3, Xylometazoline 536-33-4, Ethionamide 541-15-1,  
 Levocarnitine 546-88-3, Acetohydroxamic acid 555-30-6, Methyl dopa  
 564-25-0, Doxycycline 569-65-3, Meclizine 577-11-7, Docusate sodium  
 596-51-0, Glycopyrrolate 599-79-1, Sulfasalazine 603-50-9, Bisacodyl  
 634-03-7, Phendimetrazine 637-07-0, Clofibrate 657-24-9, Metformin  
 671-16-9, Procarbazine 672-87-7, Metyrosine 674-38-4, Bethanechol  
 723-46-6, Sulfamethoxazole 738-70-5, Trimethoprim 745-65-3,  
 Alprostadil 791-35-5, Chlophedianol 797-63-7, Levonorgestrel  
 797-64-8D, L-Norgestrel, ethinyl estradiol mixture 846-49-1, Lorazepam  
 846-50-4, Temazepam 911-45-5, Clomiphene 915-30-0, Diphenoxylate  
 962-58-3, Diazepam 968-93-4, Testolactone 972-02-1, Diphenidol  
 990-73-8, Fentanyl citrate 1134-47-0, Baclofen 1143-38-0, Anthralin  
 1321-13-7, Potassium aminobenzoate 1397-89-3, Amphotericin B  
 1400-61-9, Nystatin 1404-04-2, Neomycin 1404-04-2D, Neomycin, mixture  
 with polymyx/HC 1404-90-6, Vancomycin 1406-05-9, Penicillin  
 1491-59-4, Oxymetazoline 1622-61-3, Clonazepam 1953-02-2, Tiopronin  
 1977-10-2, Loxapine 2152-34-3, Pemoline 2152-44-5, Betamethasone  
 valerate 2447-57-6, Sulfadoxine 2451-01-6, Terpin hydrate 2609-46-3,  
 Amiloride 2809-21-4 2998-57-4, Estramustine 3116-76-5, Dicloxacillin  
 3313-26-6, Thiothixene 3385-03-3, Flunisolide 3485-14-1, Cyclacillin  
 3737-09-5, Disopyramide

RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); BIOL (Biological study)

(methods of determining individual hypersensitivity to a pharmaceutical

from gene expression profile)

IT 3778-73-2, Iphosphamide 3930-20-9, Sotalol 4205-90-7, Clonidine 4419-39-0, Beclomethasone 4499-40-5, Oxtriphylline, biological studies 4618-18-2, Lactulose 4697-36-3, Carbenicillin 4759-48-2, Isotretinoin 5051-62-7, Guanabenz 5543-57-7, (s)-Warfarin 5633-20-5, Oxycytinin 5786-21-0, Clozapine 6190-39-2, Dihydroergotamine mesylate 6493-05-6, Pentoxifylline 6621-47-2, Perhexiline 7020-55-5, Clidinium 7235-40-7, Beta carotene 7261-97-4, Danrolene 7416-34-4, Molindone 7439-93-2, Lithium, biological studies 7447-40-7, Potassium chloride, biological studies 7481-89-2, Zalcitabine 7487-88-9, Magnesium sulfate, biological studies 7648-98-8, Ambenonium 7681-11-0, Potassium iodide, biological studies 7681-93-8, Natamycin 7683-59-2, Isoproterenol 8029-99-0, Paregoric 8049-47-6, Pancreatin 8050-81-5, Simethicone 8063-07-8, Kanamycin 8067-24-1, Ergolid mesylates 9001-27-8, Blood-coagulation factor VIII 9001-75-6, Pepsin 9004-10-8, Insulin, biological studies 9004-67-5, Methyl cellulose 9005-49-6, Enoxaparin, biological studies 9007-92-5, Glucagon, biological studies 9039-53-6, Urokinase 9046-56-4, Ancrod 10118-90-8, Minocycline 10238-21-8, Glyburide 10262-69-8, Maprotiline 10540-29-1, Tamoxifen 11041-12-6, Cholestyramine 11056-06-7, Bleomycin 11111-12-9, Cephalosporin 12174-11-7, Attapulgit 12244-57-4, Gold sodium thiomalate 12650-69-0, Mupirocin 12794-10-4D, Benzodiazepine, derivs. 13010-47-4, Lomustine 13292-46-1, Rifampin 13311-84-7, Flutamide 13392-28-4, Rimantadine 13647-35-3, Trilostane 14028-44-5, Amoxapine 14124-50-6 14611-51-9, Selegiline 14769-73-4, Levamisole 14838-15-4, Phenylpropanolamine 14882-18-9, Bismuth subsalicylate 15301-69-6, Flavoxate 15307-86-5, Diclofenac 15663-27-1, Cisplatin 15686-71-2, Cephalaxin 15687-27-1, Ibuprofen 15722-48-2, Olsalazine 16051-77-7, Isosorbide mononitrate 16068-46-5, Potassium phosphate 16110-51-3, Cromolyn 16590-41-3, Naltrexone 16679-58-6, Desmopressin 17230-88-5, Danazol 17784-12-2, Sulfacytine 18323-44-9, Clindamycin 18559-94-9, Albuterol 18883-66-4, Streptozocin 19216-56-9, Prazosin 19794-93-5, Trazodone 20537-88-6, Amifostine 20830-75-5, Digoxin 20830-81-3, Daunomycin 21256-18-8, Oxaprozin 21829-25-4, Nifedipine 22204-53-1, Naproxen 22232-71-9, Mazindol 23031-32-5, Terbutaline sulfate 23214-92-8, Doxorubicin 23288-49-5, Probucol 25322-68-3, Polyethylene glycol 25451-15-4, Felbamate 25614-03-3, Bromocriptine 25812-30-0, Gemfibrozil 26652-09-5, Ritodrine 26787-78-0, Amoxicillin 26807-65-8, Indapamide 26839-75-8, Timolol 27203-92-5, Tramadol 27262-47-1, Levobupivacaine 27686-84-6, Masoprocol 28395-03-1, Bumetamide 28657-80-9, Cinoxacin 28782-42-5, Difenoxin 28860-95-9, Carbidoopa 28911-01-5, Triazolam 28981-97-7, Alprazolam 29094-61-9, Glipizide 29110-47-2, Guanfacine 29122-68-7, Atenolol 30516-87-1, Zidovudine 31441-78-8, Mercaptopurine 31677-93-7, Bupropion hydrochloride 31828-71-4, Mexiletine 31883-05-3, Moricizine 32986-56-4, Tobramycin 33069-62-4, Paclitaxel 33419-42-0, Etoposide 34089-81-1, Sodium ferric gluconate 35189-28-7, Norgestimate 36322-90-4, Piroxicam 36505-84-7, Buspirone 36791-04-5, Ribavirin 38304-91-5, Minoxidil 40180-04-9, Tienilic acid 40580-59-4, Guanadrel 41575-94-4, Carboplatin 41708-72-9, Tocainide 42399-41-7, Diltiazem 42924-53-8, Nabumetone 49562-28-9, Fenofibrate 50679-08-8, Terfenadine 50925-79-6, Colestipol 50972-17-3, Bacampicillin 51022-71-0, Nabilone 51110-01-1, Somatostatin 51333-22-3, Budesonide 51384-51-1, Metoprolol 51481-61-9, Cimetidine 53179-11-6, Loperamide 53230-10-7, Mefloquine 53608-75-6, Pancrelipase 53714-56-0, Leuprolide 53994-73-3, Cefaclor 54024-22-5, Desogestrel 54063-53-5, Propafenone 54143-56-5, Flecainide acetate 54182-58-0, Sucralfate 54350-48-0, Ertretinate 54573-75-0, Doxercalciferol 54910-89-3, Fluoxetine 55142-85-3, Ticlopidine

55268-75-2, Cefuroxime 55985-32-5, Nifedipine 56420-45-2, Epirubicin  
58001-44-8, 58581-89-8, Azelastine 59122-46-2, Misoprostol  
59277-89-3, Acyclovir 59729-33-8, Citalopram 59865-13-3, Cyclosporine  
A 60142-96-3, Gabapentin 60205-81-4, Ipratropium 61489-71-2,  
Menotropin 61718-82-9, Fluvoxamine maleate 61869-08-7, Paroxetine  
62571-86-2, Captopril 63585-09-1, Fosarnet sodium 63590-64-7,  
Terazosin 64952-97-2, Latamoxef 65141-46-0, Nicorandil 65277-42-1,  
Ketoconazole 66085-59-4, Nimodipine 66104-22-1, Pergolide  
66357-35-5, Ranitidine 66376-36-1, Alendronate 67227-57-0, Fenoldopam  
mesylate 68475-42-3, Anagrelide 68844-77-9, Astemizole 69049-73-6,  
Nedocromil 69123-98-4, Fialuridine 69655-05-6, Didanosine  
70359-46-5, Bromidine tartrate 70989-04-7, S-Mephenytoin 71320-77-9,  
Moclobemide 72432-03-2, Miglitol 72509-76-3, Felodipine 72956-09-3,  
Carvedilol 73590-58-6, Omeprazole 74103-06-3, Ketorolac 74191-85-8,  
Doxazosin 75330-75-5, Lovastatin 75695-93-1, Isradipine 75706-12-6,  
Leflunomide 75847-73-3, Enalapril 76470-66-1, Loracarbef 76547-98-3,  
Lisinopril 76568-02-0, Flosequin 76584-70-8 76824-35-6, Famotidine  
76932-56-4, Nafarelin 76963-41-2, Nizatidine 78110-38-0, Aztreonam  
78628-80-5, Terbinafine hydrochloride 79516-68-0, Levocabastine  
79617-96-2, Sertraline 79794-75-5, Loratadine 79902-63-9, Simvastatin  
80125-14-0, Remoxipride 80474-14-2, Fluticasone propionate 81093-37-0,  
Pravastatin 81098-60-4, Cisapride 81103-11-9, Clarithromycin  
81669-57-0, Anistreplase 82410-32-0, Ganciclovir 82419-36-1, Ofloxacin  
82626-48-0, Zolpidem 82834-16-0, Perindopril 83366-66-9, Nefazodone  
83799-24-0, Fexofenadine 83881-51-0, Cetirizine 83905-01-5,  
Azithromycin 84057-84-1, Lamotrigine 84449-90-1, Raloxifene  
84625-61-6, Itraconazole 85441-61-8, Quinapril 85721-33-1,  
Ciprofloxacin 86386-73-4, Fluconazole 86541-75-5, Benazepril  
87333-19-5, Ramipril 87679-37-6, Trandolapril 88040-23-7, Cefepime  
88150-42-9, Amlodipine 89365-50-4, Salmeterol 89778-26-7, Toremifene  
90566-53-3, Fluticasone 91714-94-2, Bromfenac  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); BIOL (Biological study)

(methods of determining individual hypersensitivity to a pharmaceutical

agent

from gene expression profile)

IT 302-79-4, Tretinoin 59122-46-2, Misoprostol

RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); BIOL (Biological study)

(methods of determining individual hypersensitivity to a pharmaceutical


agent

from gene expression profile)

RN 302-79-4 CAPLUS

CN Retinoic acid (CA INDEX NAME)

Double bond geometry as shown.




RN 59122-46-2 CAPLUS

CN Prost-13-en-1-oic acid, 11,16-dihydroxy-16-methyl-9-oxo-, methyl ester,

(11 $\alpha$ ,13E)-(±)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



L6 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2008 ACS on SIN

ABSTRACT:

Compds. or their salts of general formula (I): A-B-N(O)<sub>s</sub> wherein: s is an integer equal to 1 or 2; A = R-T1-, wherein R is the drug radical and T1 = (CO)t or (X)t', wherein X = O, S, NR1c, R1c is H or a linear or branched alkyl or a free valence, t and t' are integers and equal to zero or 1, with the proviso that t = 1 when t' = 0; t = 0 when t' = 1; B = -TB -X2-O- wherein TB = (CO) when t = 0, TB = X when t' = 0, X being as above defined; X2, bivalent radical, is such that the precursor drug of A and the precursor of B meet resp. the pharmacol. tests described in the description. Synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction are disclosed. The precursors are such as to meet the pharmacol. test reported in the description.

ACCESSION NUMBER: 2001:137173 CAPLUS

DOCUMENT NUMBER: 134:178396

TITLE: Synthesis, activity and formulations of pharmaceutical compounds for treatment of oxidative stress and/or endothelial dysfunction

INVENTOR(S): Del Soldato, Piero

PATENT ASSIGNEE(S): Nicox S.A., Fr.

SOURCE: PCT Int. Appl., 94 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	--	-----	-----	-----
WO 2001012584	A2	20010222	WO 2000-EP7225	20000727 <--
WO 2001012584	A3	20020829		
W:	AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
IT 99MI1817	A1	20010212	IT 1999-MI1817	19990812 <--

CA 2381409	A1	20010222	CA 2000-2381409	20000727 <--
BR 2000013264	A	20020416	BR 2000-13264	20000727 <--
EP 1252133	A2	20021030	EP 2000-953102	20000727 <--
EP 1252133	B1	20050608		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL

HU 2002003939	A2	20030328	HU 2002-3939	20000727 <--
HU 2002003939	A3	20041228		
JP 2003515526	T	20030507	JP 2001-516885	20000727 <--
CN 1433396	A	20030730	CN 2000-814049	20000727 <--
NZ 516889	A	20041029	NZ 2000-516889	20000727 <--
AU 781643	B2	20050602	AU 2000-65670	20000727 <--
AT 297375	T	20050615	AT 2000-953102	20000727 <--
EP 1593664	A1	20051109	EP 2005-104064	20000727 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, FI, RO, CY

RU 2264383	C2	20051120	RU 2002-103509	20000727 <--
ES 2243292	T3	20051201	ES 2000-953102	20000727 <--
NZ 535559	A	20051223	NZ 2000-535559	20000727 <--
CN 1923797	A	20070307	CN 2006-10136231	20000727 <--
ZA 2002000628	A	20030423	ZA 2002-628	20020123 <--
US 7186753	B1	20070306	US 2002-48469	20020207 <--
NO 2002000623	A	20020409	NO 2002-623	20020208 <--
MX 2002PA01519	A	20020702	MX 2002-PA1519	20020211 <--
AU 2005202824	A1	20050721	AU 2005-202824	20050628
IN 2006CN01908	A	20070608	IN 2006-CN1908	20060530
KR 760394	B1	20070919	KR 2006-724051	20061116
US 20070197499	A1	20070823	US 2006-642783	20061221

PRIORITY APPLN. INFO.:

IT 1999-MI1817	A	19990812
CN 2000-814049	A3	20000727
EP 2000-953102	A3	20000727
IN 2002-CN187	A3	20000727
WO 2000-EP7225	W	20000727
US 2002-48469	A1	20020207
KR 2002-701883	A3	20020209

OTHER SOURCE(S): MARPAT 134:178396

PI	WO 2001012584	A2	<u>20010222</u>		
	PATENT NO.		KIND	DATE	APPLICATION NO.
	-----		----	-----	-----
PI	WO 2001012584	A2	20010222	WO 2000-EP7225	20000727 <--
	WO 2001012584	A3	20020829		

W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GD, GE,  
HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG,  
MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN,  
YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,  
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

IT 99MI1817	A1	20010212	IT 1999-MI1817	19990812 <--
CA 2381409	A1	20010222	CA 2000-2381409	20000727 <--
BR 2000013264	A	20020416	BR 2000-13264	20000727 <--
EP 1252133	A2	20021030	EP 2000-953102	20000727 <--
EP 1252133	B1	20050608		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL

HU 2002003939	A2	20030328	HU 2002-3939	20000727 <--
HU 2002003939	A3	20041228		
JP 2003515526	T	20030507	JP 2001-516885	20000727 <--

CN	1433396	A	20030730	CN	2000-814049	20000727 <--
NZ	516889	A	20041029	NZ	2000-516889	20000727 <--
AU	781643	B2	20050602	AU	2000-65670	20000727 <--
AT	297375	T	20050615	AT	2000-953102	20000727 <--
EP	1593664	A1	20051109	EP	2005-140464	20000727 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,						
IE, SI, LT, FI, RO, CY						
RU	2264383	C2	20051120	RU	2002-103509	20000727 <--
ES	2243292	T3	20051201	ES	2000-953102	20000727 <--
NZ	535559	A	20051223	NZ	2000-535559	20000727 <--
CN	1923797	A	20070307	CN	2006-10136231	20000727 <--
ZA	2002000628	A	20030423	ZA	2002-628	20020123 <--
US	7186753	B1	20070306	US	2002-48469	20020207 <--
NO	2002000623	A	20020409	NO	2002-623	20020208 <--
MX	2002PA01519	A	20020702	MX	2002-PA1519	20020211 <--
AU	2005202824	A1	20050721	AU	2005-202824	20050628
IN	2006CN01908	A	20070608	IN	2006-CN1908	20060530
KR	760394	B1	20070919	KR	2006-724051	20061116
US	20070197499	A1	20070823	US	2006-642783	20061221
IT	50-44-2, 6-Mercaptopurine 51-21-8, Fluorouracil 53-79-2, Puromycin					
	54-25-1, 6-Azauridine 57-22-7, Vincristine 59-05-2, Methotrexate					
	69-33-0, Tubercidin 84-16-2, Hexestrol 115-02-6, Azaserine 147-94-4,					
	Cytarabine 148-82-3, Melphalan 154-42-7, Thioguanine 157-03-9,					
	6-Diazo-5-oxo-L-norleucine 302-79-4, Retinoic acid 305-03-3,					
	Chlorambucil 320-67-2, Azacitidine 477-30-5, Demecolcine 488-41-5,					
	Mitobronitol 576-68-1, Mannomustine 801-52-5, Porfiromycin 865-21-4,					
	Vinblastine 1404-15-5, Nogalamycin 1853-37-8, Podophyllin acid					
	2179-16-0, Ninopterin 2363-58-8, Epitiostanol 3094-09-5, Doxifluridine					
	3733-81-1, Defosfamide 3930-19-6, Streptonigrin 4803-27-4, Anthramycin					
	5581-52-2, Thiamiprine 10318-26-0, Mitolactol 13665-88-8, Mopidamol					
	18378-89-7, Plomicin 18883-66-4, Streptozocin 20830-81-3,					
	Daunorubicin 21679-14-1, Fludarabine 22006-84-4, Denopterin					
	22668-01-5, Etanidazole 24280-93-1, Mycophenolic acid 27778-66-1,					
	Tenuazonic acid 29776-20-2, Teniposide 31698-14-3, Ancitabine					
	33069-62-4, Paclitaxel 33419-42-0, Etoposide 50264-69-2, Lonidamine					
	50935-04-1, Carubicin 52128-35-5, Trimetrexate 53643-48-4, Vindesine					
	53910-25-1, Pentostatin 54083-22-6, Zorubicin 54749-90-5,					
	Chlorozotocin 55726-47-1, Enocitabine 56420-45-2, Epirubicin					
	58957-92-9, Idarubicin 58970-76-6, Ubenimex 58994-96-0, Ranimustine					
	65271-80-9, Mitoxantrone 65646-68-6, Fenretinide 70052-12-9,					
	Eflornithine 71486-22-1, Vinorelbine 71628-96-1, Menogaril					
	72496-41-4, Pirarubicin 72732-56-0, Piritrexim 80576-83-6, Edatrexate					
	82413-20-5, Droloxifene 84088-42-6, Roquinimex 87806-31-3, Porfimer					
	sodium 90357-06-5, Bicalutamide 95058-81-4, Gemcitabine 106486-76-4,					
	Carzinophilin 112887-68-0, Tomudex 114977-28-5, Docetaxel					
	123948-87-8, Topotecan 126595-07-1, Propagermanium					
	RL: RCT (Reactant); RACT (Reactant or reagent)					
	(antitumor; synthesis, activity and formulations of pharmaceutical					
	comps. for treatment of oxidative stress and/or endothelial					
	dysfunction)					
IT	57-08-9, s-Acetamidocaproic acid 33159-27-2, Ecabet					
	34675-84-8, Cetraxate 51481-61-9, Cimetidine 55028-70-1, Arbaciprostil					
	56695-65-9, Rosaprostol 57381-26-7, Irsogladine 59122-46-2,					
	Misoprostol 64204-55-3, Esaprazole 64218-02-6, Plauonol 64506-49-6,					
	Sofalcone 69900-72-7, Trimoprostil 70667-26-4 73121-56-9, Enprostil					
	73590-58-6, Omeprazole 77287-05-9, Rioprostil 92071-51-7, Rotraxate					
	102625-70-7, Pantoprazole					
	RL: RCT (Reactant); RACT (Reactant or reagent)					

(antiulcer; synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction)

IT 302-79-4, Retinoic acid


RL: RCT (Reactant); RACT (Reactant or reagent)

(antitumor; synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction)

RN 302-79-4 CAPLUS

CN Retinoic acid (CA INDEX NAME)

Double bond geometry as shown.



IT 59122-46-2, Misoprostol

RL: RCT (Reactant); RACT (Reactant or reagent)


(antiulcer; synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction)

RN 59122-46-2 CAPLUS

CN Prost-13-en-1-oic acid, 11,16-dihydroxy-16-methyl-9-oxo-, methyl ester, (11 $\alpha$ ,13E)-(±)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



L6 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ABSTRACT:

Synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction are disclosed. The precursors are such as to meet the pharmacol. test reported in the description.

ACCESSION NUMBER: 2000:742057 CAPLUS

DOCUMENT NUMBER: 133:309791

TITLE: Synthesis, activity and formulations of pharmaceutical compounds for treatment of oxidative stress and/or endothelial dysfunction

INVENTOR(S): Del Soldato, Piero  
 PATENT ASSIGNEE(S): Nicox S.A., Fr.  
 SOURCE: PCT Int. Appl., 140 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000061541	A2	20001019	WO 2000-EP3239	20000411 <--
WO 2000061541	A3	20010927		
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, DM, EE, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
IT 1311923	B1	20020320	IT 1999-MI752	19990413 <--
CA 2370425	A1	20001019	CA 2000-2370425	20000411 <--
BR 2000009703	A	20020108	BR 2000-9703	20000411 <--
EP 1169298	A2	20020109	EP 2000-926870	20000411 <--
EP 1169298	B1	20060104		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
JP 2002541236	T	20021203	JP 2000-610818	20000411 <--
TR 200102928	T2	20021223	TR 2001-2928	20000411 <--
HU 2002000714	A2	20021228	HU 2002-714	20000411 <--
HU 2002000714	A3	20030128		
NZ 514270	A	20040227	NZ 2000-514270	20000411 <--
RU 2237057	C2	20040927	RU 2001-127574	20000411 <--
AU 777579	B2	20041021	AU 2000-45474	20000411 <--
AT 315021	T	20060215	AT 2000-926870	20000411 <--
PT 1169298	T	20060531	PT 2000-926870	20000411 <--
ES 2256001	T3	20060716	ES 2000-926870	20000411 <--
PL 193919	B1	20070430	PL 2000-350967	20000411 <--
ZA 2001008126	A	20030403	ZA 2001-8126	20011003 <--
MX 2001PA10213	A	20020918	MX 2001-PA10213	20011009 <--
KR 803345	B1	20080213	KR 2001-712914	20011009 <--
NO 2001004928	A	20011213	NO 2001-4928	20011010 <--
US 6987120	B1	20060117	US 2001-926322	20011015 <--
US 20060030605	A1	20060209	US 2005-234084	20050926
PRIORITY APPLN. INFO.:			IT 1999-MI752	A 19990413
			WO 2000-EP3239	W 20000411
			US 2001-926322	A3 20011015

OTHER SOURCE(S): MARPAT 133:309791

PI	WO 2000061541 A2	20001019		
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000061541	A2	WO 2000-EP3239	20000411 <--
	WO 2000061541	A3		
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, DM, EE, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,				



DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

IT 1311923	B1	20020320	IT 1999-MI752	19990413 <--
CA 2370425	A1	20001019	CA 2000-2370425	20000411 <--
BR 2000009703	A	20020108	BR 2000-9703	20000411 <--
EP 1169298	A2	20020109	EP 2000-926870	20000411 <--
EP 1169298	B1	20060104		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, CY

JP 2002541236	T	20021203	JP 2000-610818	20000411 <--
TR 200102928	T2	20021223	TR 2001-2928	20000411 <--
HU 2002000714	A2	20021228	HU 2002-714	20000411 <--
HU 2002000714	A3	20030128		
NZ 514270	A	20040227	NZ 2000-514270	20000411 <--
RU 2237057	C2	20040927	RU 2001-127574	20000411 <--
AU 777579	B2	20041021	AU 2000-45474	20000411 <--
AT 315021	T	20060215	AT 2000-926870	20000411 <--
PT 1169298	T	20060531	PT 2000-926870	20000411 <--
ES 2256001	T3	20060716	ES 2000-926870	20000411 <--
PL 193919	B1	20070430	PL 2000-350967	20000411 <--
ZA 2001008126	A	20030403	ZA 2001-8126	20011003 <--
MX 2001PA10213	A	20020918	MX 2001-PA10213	20011009 <--
KR 803345	B1	20080213	KR 2001-712914	20011009 <--
NO 2001004928	A	20011213	NO 2001-4928	20011010 <--
US 6987120	B1	20060117	US 2001-926322	20011015 <--
US 20060030605	A1	20060209	US 2005-234084	20050926

IT 50-44-2, 6-Mercaptopurine 51-21-8, Fluorouracil 53-79-2, Puromycin  
54-25-1, 6-Azaauridine 57-22-7, Vincristine 59-05-2, Methotrexate  
69-33-0, Tubercidin 84-16-2, Hexestrol 115-02-6, Azaserine 147-94-4,  
Cytarabine 148-82-3, Melphalan 154-42-7, Thioguanine 157-03-9,  
6-Diazo-5-oxo-L-norleucine 302-79-4, Retinoic acid 305-03-3,  
Chlorambucil 320-67-2, Azacitidine 477-30-5, Demecolcine 488-41-5,  
Mitobronitol 576-68-1, Mannomustine 801-52-5, Porfiriomycin 865-21-4,  
Vinblastine 1404-15-5, Nogalamycin 1853-37-8, Podophyllic acid  
2179-16-0, Ninopterin 2363-58-8, Eptiostanol 3094-09-5, Doxifluridine  
3733-81-1, Defosfamide 3930-19-6, Streptonigrin 4803-27-4, Anthramycin  
5581-52-2, Thiamiprine 10318-26-0, Mitolactol 13665-88-8, Mopidamol  
18378-89-7, Plomicamycin 18883-66-4, Streptozocin 20830-81-3,  
Daunorubicin 21679-14-1, Fludarabine 22006-84-4, Deneopterin  
22668-01-5, Etanidazole 24280-93-1, Mycophenolic acid 27778-66-1,  
Tenuazonic acid 29767-20-2, Teniposide 31698-14-3, Ancitabine  
33069-62-4, Paclitaxel 33419-42-0, Etoposide 50264-69-2, Londamine  
50935-04-1, Carubicin 52128-35-5, Trimetrexate 53643-48-4, Vindesine  
53910-25-1, Pentostatin 54083-22-6, Zorubicin 54749-90-5,  
Chlorozotocin 55726-47-1, Enocitabine 56420-45-2, Epirubicin  
58957-92-9, Idarubicin 58970-76-6, Ubenimex 58994-96-0, Ranimustine  
65271-80-9, Mitoxantrone 65646-68-6, Fenretinide 66004-77-1  
70052-12-9, Eflornithine 71486-22-1, Vinorelbine 71628-96-1, Menogaril  
72496-41-4, Pirarubicin 72732-56-0, Piritrexim 80576-83-6, Edatrexate  
82413-20-5, Droloxifene 84088-42-6, Roquinimex 87806-31-3, Porfimer  
sodium 90357-06-5, Bicalutamide 106486-76-4, Carzinophilin  
112887-68-0, Tomudex 114977-28-5, Docetaxel 123948-87-8, Topotecan  
126595-07-1, Propagermanium

RL: RCT (Reactant); RACT (Reactant or reagent)  
(antitumor; synthesis, activity and formulations of pharmaceutical  
compds. for treatment of oxidative stress and/or endothelial  
dysfunction)

IT 57-08-9,  $\epsilon$ -Acetamidocaproic acid 33159-27-2, Ecabet

34675-84-8, Cetraxate 51481-61-9, Cimetidine 55028-70-1, Arbabrostil  
 56695-65-9, Rosaprostol 57381-26-7, Irsogladine 59122-46-2,  
 Misoprostol 64204-55-3, Esaprazole 64218-02-6, Plaunotol 64506-49-6,  
 Sofalcone 69900-72-7, Trimoprostil 70667-26-4 73121-56-9, Enprostil  
 73590-58-6, Omeprazole 77287-05-9, Rioprostil 92071-51-7, Rotraxate  
 102625-70-7, Pantoprazole

RL: RCT (Reactant); RACT (Reactant or reagent)  
 (antiulcer; synthesis, activity and formulations of pharmaceutical  
 compds. for treatment of oxidative stress and/or endothelial  
 dysfunction)


IT 302-79-4, Retinoic acid

RL: RCT (Reactant); RACT (Reactant or reagent)  
 (antitumor; synthesis, activity and formulations of pharmaceutical  
 compds. for treatment of oxidative stress and/or endothelial  
 dysfunction)

RN 302-79-4 CAPLUS

CN Retinoic acid (CA INDEX NAME)

Double bond geometry as shown.



IT 59122-46-2, Misoprostol


RL: RCT (Reactant); RACT (Reactant or reagent)  
 (antiulcer; synthesis, activity and formulations of pharmaceutical  
 compds. for treatment of oxidative stress and/or endothelial  
 dysfunction)

RN 59122-46-2 CAPLUS

CN Prost-13-en-1-oic acid, 11,16-dihydroxy-16-methyl-9-oxo-, methyl ester,  
 (11 $\alpha$ ,13E)-(±)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



L6 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ABSTRACT:

Compds. A-B-C-N(O)s and A-Cl[N(O)s]-B1 or their salts [s is an integer 1 or 2,  
 preferably s = 2; A is the radical of a drug and is such as to meet the

pharmacol. tests reported in the description; C and Cl are two bivalent radicals; the precursors of the radicals B and Bl are such as to meet the pharmacol. test reported in the description] were prepared for use as pharmaceuticals. Thus, (S,S)-N-acetyl-S-(6-methoxy- $\alpha$ -methyl-2-naphthalenylacetyl)cysteine 4-nitroxybutyl ester was prepared (NCX 2101) from naproxene and N-acetylcysteine in the first of 28 synthetic examples given. Pharmacol. test examples and tabular data are also given.

ACCESSION NUMBER: 2000:742053 CAPLUS  
DOCUMENT NUMBER: 133:310142  
TITLE: Synthesis, activity and formulations of pharmaceutical compounds for treatment of oxidative stress and/or endothelial dysfunction  
INVENTOR(S): Del Soldato, Piero  
PATENT ASSIGNEE(S): Nicox S.A., Fr.  
SOURCE: PCT Int. Appl., 159 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000061537	A2	20001019	WO 2000-EP3234	20000411 <--
WO 2000061537	A3	20010927		
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, DM, EE, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
IT 1311924	B1	20020320	IT 1999-MI753	19990413 <--
CA 2370412	A1	20001019	CA 2000-2370412	20000411 <--
BR 2000009702	A	20020108	BR 2000-9702	20000411 <--
EP 1169294	A2	20020109	EP 2000-925203	20000411 <--
EP 1169294	B1	20071205		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
JP 2002541233	T	20021203	JP 2000-610814	20000411 <--
HU 2002003378	A2	20030128	HU 2002-3378	20000411 <--
HU 2002003378	A3	20040728		
NZ 514267	A	20040625	NZ 2000-514267	20000411 <--
RU 2237657	C2	20041010	RU 2001-127576	20000411 <--
AU 778989	B2	20041223	AU 2000-44001	20000411 <--
AT 380170	T	20071215	AT 2000-925203	20000411 <--
ES 2296616	T3	20080501	ES 2000-925203	20000411 <--
ZA 2001008127	A	20030103	ZA 2001-8127	20011003 <--
MX 2001PA10210	A	20020918	MX 2001-PA10210	20011009 <--
NO 2001004927	A	20011213	NO 2001-4927	20011010 <--
US 6869974	B1	20050322	US 2001-926326	20011015 <--
US 20050261242	A1	20051124	US 2004-24857	20041230
US 7378412	B2	20080527		
PRIORITY APPLN. INFO.:			IT 1999-MI753	A 19990413
			WO 2000-EP3234	W 20000411
			US 2001-926326	A3 20011015

OTHER SOURCE(S): MARPAT 133:310142

PI	WO 2000061537 A2	<u>20001019</u>			
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000061537	A2	20001019	WO 2000-EP3234	20000411 <--
	WO 2000061537	A3	20010927		
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, DM, EE, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
IT	1311924	B1	20020320	IT 1999-MI753	19990413 <--
CA	2370412	A1	20001019	CA 2000-2370412	20000411 <--
BR	2000009702	A	20020108	BR 2000-9702	20000411 <--
EP	1169294	A2	20020109	EP 2000-925203	20000411 <--
EP	1169294	B1	20071205		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
JP	2002541233	T	20021203	JP 2000-610814	20000411 <--
HU	2002003378	A2	20030128	HU 2002-3378	20000411 <--
HU	2002003378	A3	20040728		
NZ	514267	A	20040625	NZ 2000-514267	20000411 <--
RU	2237657	C2	20041010	RU 2001-127576	20000411 <--
AU	778989	B2	20041223	AU 2000-44001	20000411 <--
AT	380170	T	20071215	AT 2000-925203	20000411 <--
ES	2296616	T3	20080501	ES 2000-925203	20000411 <--
ZA	2001008127	A	20030103	ZA 2001-8127	20011003 <--
MX	2001PA10210	A	20020918	MX 2001-PA10210	20011009 <--
NO	2001004927	A	20011213	NO 2001-4927	20011010 <--
US	6869974	B1	20050322	US 2001-926326	20011015 <--
US	20050261242	A1	20051124	US 2004-24857	20041230
US	7378412	B2	20080527		
IT	50-33-9, Phenylbutazone, reactions		50-44-2, Mercaptopurine		50-59-9,
	Cephaloridine 50-91-9, Floxuridine		51-21-8, Fluorouracil		51-43-4,
	Epinephrine 51-45-6, Histamine, reactions		53-79-2, Puromycin		
	54-25-1, Azauridine 54-42-2, Idoxuridine		54-80-8, Pronethalol		
	54-85-3, Isoniazid 56-75-7, Chloramphenicol		56-81-5D, Glycerol, iodo		
	derivative 57-08-9, <i>o</i> -Acetamidocaproic acid		57-22-7, Vincristine		
	57-27-2, Morphine, reactions		57-50-1, reactions		57-62-5 57-67-0,
	Sulfaguanidine 57-68-1, Sulfamethazine		57-92-1, Streptomycin,		
	reactions 58-32-2, Dipyrindamole		59-05-2, Methotrexate		60-00-4,
	Edetic acid, reactions		60-54-8, Tetracycline		61-24-5, CephalosporinC
	61-33-6, Benzylpenicillinic acid, reactions		61-68-7, Mefenamic acid		
	61-72-3, Cloxacillin		63-74-1, Sulfanilamide		65-45-2 65-49-6,
	<i>p</i> -Aminosalicylic acid		66-79-5, Oxacillin		68-26-8, Vitamin A
	68-41-7, Cycloserine		68-88-2, Hydroxyzine		68-90-6,
	Benziodarone 69-33-0, Tubercidin		70-00-8, Trifluridine		72-14-0,
	Sulfathiazole		74-31-7, <i>N,N'</i> -Diphenyl- <i>p</i> -phenylenediamine		74-55-5,
	Ethambutol		74-79-3, Arginine, reactions		76-41-5, Oxymorphone
	76-42-6, Oxycodone		76-57-3, Codeine		76-58-4, Ethylmorphine
	77-07-6, Levorphanol		79-57-2, Oxytetracycline		80-02-4, 2- <i>p</i> -
	Sulfanilylanilinoethanol		80-03-5, Acediasulfone		80-08-0,
	4,4'-Sulfonyldianiline		80-32-0, Sulfachlorpyridazine		80-35-3,
	Sulfamethoxypyridazine		80-53-5, Terpin		84-16-2, Hexestrol
	87-08-1, Penicillin V		87-09-2, Penicillin O		87-28-5, Glycolsalicylate
	89-45-2, Salicylsulfuric acid		90-05-1, Guaiacol		91-53-2, Ethoxyquin
	93-14-1, Guaifenesin		94-10-0, Ethoxazene		94-19-9, Sulfaethidole

97-53-0, Eugenol 97-54-1, Isoeugenol 98-54-4 98-92-0, Nicotinamide  
 100-55-0, Nicotiny alcohol 101-91-7, 4'-Hydroxybutyranilide 103-12-8,  
 Sulfamidochrysoidine 103-97-9, Phenocoll 110-17-8, Fumaric acid,  
 reactions 111-17-1, 3,3'-Thiodipropionic acid 113-98-4, Penicillin G  
 potassium salt 114-07-8, Erythromycin 115-02-6, Azaserine 115-68-4,  
 Sulfadiazine 116-42-7, Sulfaproxyline 116-44-9, Sulfapyrazine  
 118-55-8, Phenyl salicylate 118-57-0, Acetaminosalol 118-98-2, Tocol  
 120-34-3, n-Sulfanilyl-3,4-xylamide 121-00-6, 3-tert-Butyl-4-  
 hydroxyanisole 121-79-9, Propyl gallate 122-11-2, Sulfadimethoxine  
 125-28-0, Dihydrocodeine 125-29-1, Hydrocodone 127-07-1, Hydroxyurea  
 127-33-3, Demeclocycline 127-35-5, Phenazocine 127-69-5, Sulfisoxazole  
 127-71-9, Sulfamerazine 127-79-7, Sulfamerazine 128-37-0,  
 3,5-Di-tert-Butyl-4-hydroxytoluene, reactions 128-46-1,  
 Dihydrostreptomycin 129-20-4, Oxyphenbutazone 130-16-5, Cloxyquin  
 132-60-5, Cinchophen 132-92-3, Methicillin sodium salt 132-93-4,  
 Phenethicillin potassium salt 133-11-9, Phenylaminosalicylate  
 134-55-4, Phenylacetylsalicylate 136-70-9, Protokylol 138-52-3,  
 Salicin 143-52-2, Metopon 144-14-9, Anileridine 144-80-9,  
 Sulfacetamide 144-82-1, Sulfamethizole 144-83-2, Sulfapyridine  
 147-94-4, Cytarabine 148-24-3, 8-Quinololinol, reactions 148-82-3,  
 Melfalan 152-47-6, Sulfalene 153-61-7, Cephalothin 154-21-2,  
 Lincomycin 154-42-7, Thioguanine 157-03-9, 6-Diazo-5-oxo-L-norleucine  
 299-42-3, Ephedrine 302-79-4, Retinoic acid 303-81-1,  
 Novobiocin 305-03-3, Chlorambucil 315-30-0, Allopurinol 320-67-2,  
 Azacitidine 322-79-2, Triflusal 339-43-5, Carbutamide 359-83-1,  
 Pentazocine 389-08-2 390-64-7, Prenylamine 395-28-8, Isoxsuprine  
 404-86-4, Capsaicin 427-00-9, Desomorphine 437-74-1, Xanthinol  
 niacinate 443-48-1, Metronidazole 447-41-6, Nylidrin 456-59-7,  
 Cyclocladate 458-35-5 458-37-7, Curcumin 466-97-7, Normorphine  
 466-99-9, Hydromorphone 468-56-4, Hydroxypethidine 473-30-3,  
 Thiazolsulfone 477-30-5, Demecolcine 485-41-6, Sulfachrysoidine  
 486-79-3, Dipyracetyl 487-48-9, Salacetamide 488-41-5, Mitobronitol  
 495-76-1, Piperonyl alcohol 495-84-1, Salinazid 497-75-6 498-71-5,  
 Sobrerol 501-94-0, 4-Hydroxyphenethyl alcohol 509-60-4,  
 Dihydromorphine 515-49-1, Sulfathiourea 515-59-3, Sulfamethylthiazole  
 515-64-0, Sulfisomidine 515-69-5, Bisabolol 518-28-5, Podophyllotoxin  
 519-37-9, Etofylline 525-94-0, Penicillin N 526-08-9, Sulfaphenazole  
 526-84-1, Dihydroxymaleic acid 530-08-5, Isoetharine 530-75-6,  
 Acetylsalicylsalicylic acid 530-78-9, Flufenamic acid 533-73-3,  
 Hydroxyhydroquinone 536-24-3, Ethylnorepinephrine 539-08-2,  
 p-Lactophenetic 545-90-4, Dimheptanol 547-44-4, Sulfanilylurea  
 547-52-4, Sulfanilylsulfanilamide 547-53-5 551-27-9, Propicillin  
 552-94-3, Salsalate 553-69-5, Benzenemethanol, .a.-[(2-  
 pyridinylamino)methyl]- 562-26-5, Phenoperidine 574-77-6, Papaveroline  
 576-68-1, Mannomustine 577-85-5, 3-Hydroxyflavone 581-64-6, Thionine  
 586-06-1, Metaproterenol 599-88-2, Sulfaperine 603-00-9, Proxiphylline  
 610-88-8 632-00-8, Sulfasomizole 635-65-4, Bilirubin, reactions  
 639-48-5, Nicomorphine 644-62-2, Meclofenamic acid 651-06-9, Sulfameter  
 652-37-9, Acefylline 723-46-6, Sulfamethoxazole 729-99-7, Sulfamoxole  
 751-97-3, Rolitettracycline 768-94-5, Amantadine 801-52-5, Porfiromycin  
 808-26-4, Sancycline 824-46-4, Methoxyhydroquinone 840-50-6, MADU  
 865-21-4, Vinblastine 959-10-4, Xenbucin 987-78-0, Citicoline  
 992-21-2, Lymecycline 1077-28-7, Thiocetic acid 1083-57-4, Bucetin  
 1110-80-1, Pipacycline 1159-93-9, Clobenzepam 1174-11-4, Xenazoic acid  
 1181-54-0, Clomocycline 1400-61-9, Nystatin 1403-66-3, Gentamicin  
 1404-04-2, Neomycin 1404-15-5, Nogalamycin 1406-18-4, Vitamin E  
 1503-53-3, 5-Bromosalicylic acid acetate 1531-12-0, Norlevorphanol  
 1553-60-2, Ibufenac 1596-63-0, Quinacillin 1614-20-6, Nifurpazine

1695-77-8, Spectinomycin 1853-37-8, Podophyllicacid 1926-49-4,  
Clometocillin 1953-02-2, Tiopronin 1984-94-7, Sulfasymazine  
2013-58-3, Meclocycline 2016-63-9, Bamifylline 2030-63-9, Clofazimine  
2055-44-9, Perisoxal 2179-16-0, Ninopterin 2315-08-4,  
Salazosulfamididine 2316-64-5, Bromosaligenin 2363-58-8, Eptiostanol  
2373-80-0, 3,4-Methylenedioxycinnamic acid 2447-57-6, Sulfadoxine  
2750-76-7, Rifamide

RL: RCT (Reactant); RACT (Reactant or reagent)  
(drug precursor)

IT 52-90-4, L-Cysteine, reactions 53-86-1, Indomethacin 89-57-6,  
Mesalamine 103-90-2, Paracetamol 321-64-2, Tacrine 18683-91-5,  
Ambroxol 59122-46-2, Misoprostol 66376-36-1, Alendronic acid  
73590-58-6, Omeprazole 164790-49-2

RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); RCT (Reactant); THU (Therapeutic use); BIOL  
(Biological study); RACT (Reactant or reagent); USES (Uses)  
(synthesis, activity and formulations of pharmaceutical compds. for  
treatment of oxidative stress and/or endothelial dysfunction)


IT 302-79-4, Retinoic acid

RL: RCT (Reactant); RACT (Reactant or reagent)  
(drug precursor)

RN 302-79-4 CAPLUS

CN Retinoic acid (CA INDEX NAME)

Double bond geometry as shown.



IT 59122-46-2, Misoprostol


RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); RCT (Reactant); THU (Therapeutic use); BIOL  
(Biological study); RACT (Reactant or reagent); USES (Uses)  
(synthesis, activity and formulations of pharmaceutical compds. for  
treatment of oxidative stress and/or endothelial dysfunction)

RN 59122-46-2 CAPLUS

CN Prost-13-en-1-oic acid, 11,16-dihydroxy-16-methyl-9-oxo-, methyl ester,  
(11 $\alpha$ ,13E)-(±)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



L6 ANSWER 7 OF 9 USPATFULL on STN  
ABSTRACT:

Compounds or their salts of general formula (I): A--B--N(O).sub.s wherein: s is an integer equal to 1 or 2; A=R--T.sub.1--', wherein R is the drug radical and T.sub.1=(CO).sub.t or (X).sub.t', wherein X=O, S, NR.sub.1c, R.sub.1c is H or a linear or branched alkyl or a free valence, t and t' are integers and equal to zero or 1, with the proviso that t=1 when t'=0; t=0 when t'=1; B--T.sub.B--X.sub.2--O-- wherein T.sub.B=(CO) when t=0, T.sub.B=X when t'=0, X being as above defined; X.sub.2 is equal to R.sub.1B--X--R.sub.2B radical wherein X is as above defined, R.sub.1B and R.sub.2B, equal to or different from each other, are linear or branched C.sub.1-C.sub.6 alkylenes, or X.sub.2 is a radical wherein two alkylene chains C.sub.1-C.sub.4 are linked to nonadjacent positions of a central ring having 4 or 6 atoms, said ring being an unsaturated cycloaliphatic ring, or a saturated or aromatic heterocyclic ring, containing one or two heteroatoms, equal or different, selected from O, S, N; wherein the unsaturated cycloaliphatic ring does not have aromatic character according to Huckel's rule.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2007:58513 USPATFULL  
TITLE: Pharmaceutical compounds  
INVENTOR(S): Del Soldato, Piero, Milan, ITALY  
PATENT ASSIGNEE(S): Nicox S.A., Sophia Antipolis, FRANCE (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 7186753	B1	20070306	
	WO 2001012584		20010222	<--
APPLICATION INFO.:	US 2000-48469		20000727	<-- (10)
	WO 2000-EP7225		20000727	<--
			20020207	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	IT 1999-MI1817	19990812
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Zucker, Paul A.	
LEGAL REPRESENTATIVE:	Arent Fox PLLC	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1,11,18	
LINE COUNT:	2548	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AI	20000727	
	20020207	PCT 371 date
IT	50-44-2, 6-Mercaptopurine	51-21-8, Fluorouracil
	54-25-1, 6-Azauridine	57-22-7, Vincristine
	69-33-0, Tubercidin	84-16-2, Hexestrol
	147-94-4, Cytarabine	148-82-3, Melphalan
	157-03-9, 6-Diazo-5-oxo-L-norleucine	<u>302-79-4</u> , Retinoic acid
	305-03-3, Chlorambucil	320-67-2, Azacitidine
	488-41-5, Mitobronitol	576-68-1, Mannomustine
	865-21-4, Vinblastine	1404-15-5, Nogalamycin
		1853-37-8, Podophyllic
		53-79-2, Puromycin
		59-05-2, Methotrexate
		115-02-6, Azaserine
		154-42-7, Thioguanine
		477-30-5, Demecolcine
		801-52-5, Porfiromycin

acid 2179-16-0, Ninopterin 2363-58-8, Epitiostanol 3094-09-5,  
 Doxifluridine 3733-81-1, Defosfamide 3930-19-6, Streptonigrin  
 4803-27-4, Anthramycin 5581-52-2, Thiamiprine 10318-26-0, Mitolactol  
 13665-88-8, Mopidamol 18378-89-7, Plicamycin 18883-66-4, Streptozocin  
 20830-81-3, Daunorubicin 21679-14-1, Fludarabine 22006-84-4,  
 Denopterin 22668-01-5, Etanidazole 24280-93-1, Mycophenolic acid  
 27778-66-1, Tenuazonic acid 29767-20-2, Teniposide 31698-14-3,  
 Ancitabine 33069-62-4, Paclitaxel 33419-42-0, Etoposide 50264-69-2,  
 Lonidamine 50935-04-1, Carubicin 52128-35-5, Trimetrexate  
 53643-48-4, Vindesine 53910-25-1, Pentostatin 54083-22-6, Zorubicin  
 54749-90-5, Chlorozotocin 55726-47-1, Enocitabine 56420-45-2,  
 Epirubicin 58957-92-9, Idarubicin 58970-76-6, Ubenimex 58994-96-0,  
 Ranimustine 65271-80-9, Mitoxantrone 65646-68-6, Fenretinide  
 70052-12-9, Eflornithine 71486-22-1, Vinorelbine 71628-96-1,  
 Menogaril 72496-41-4, Pirarubicin 72732-56-0, Piritrexim  
 80576-83-6, Edatrexate 82413-20-5, Droloxifene 84088-42-6, Roquinimex  
 87806-31-3, Porfimer sodium 90357-06-5, Bicalutamide 95058-81-4,  
 Gemcitabine 106486-76-4, Carzinophilin 112887-68-0, Tomudex  
 114977-28-5, Docetaxel 123948-87-8, Topotecan 126595-07-1,  
 Propagermanium

(antitumor; synthesis, activity and formulations of pharmaceutical  
 compds. for treatment of oxidative stress and/or endothelial  
 dysfunction)


IT 57-08-9, *c*-Acetamidocaproic acid 33159-27-2, Ecabet  
 34675-84-8, Cetraxate 51481-61-9, Cimetidine 55028-70-1, Arbaprostil  
 56695-65-9, Rosaprostol 57381-26-7, Irsogladine 59122-46-2,  
 Misoprostol 64204-55-3, Esaprazole 64218-02-6, Plauotol  
 64506-49-6, Sofalcone 69900-72-7, Trimoprostil 70667-26-4  
 73121-56-9, Enprostil 73590-58-6, Omeprazole 77287-05-9, Rioprostil  
 92071-51-7, Rotraxate 102625-70-7, Pantoprazole

(antiulcer; synthesis, activity and formulations of pharmaceutical  
 compds. for treatment of oxidative stress and/or endothelial  
 dysfunction)

IT 302-79-4, Retinoic acid  
 (antitumor; synthesis, activity and formulations of pharmaceutical  
 compds. for treatment of oxidative stress and/or endothelial  
 dysfunction)

RN 302-79-4 USPATFULL  
 CN Retinoic acid (CA INDEX NAME)


Double bond geometry as shown.



IT 59122-46-2, Misoprostol  
 (antiulcer; synthesis, activity and formulations of pharmaceutical  
 compds. for treatment of oxidative stress and/or endothelial  
 dysfunction)  
 RN 59122-46-2 USPATFULL  
 CN Prost-13-en-1-oic acid, 11,16-dihydroxy-16-methyl-9-oxo-, methyl ester,  
 (11 $\alpha$ ,13E)-(±)- (CA INDEX NAME)



Relative stereochemistry.  
Double bond geometry as shown.



L6 ANSWER 8 OF 9 USPATFULL on STN  
ABSTRACT:

Compounds of their salts having general formulas (I) and (II) wherein: s= is an integer equal to 1 or 2, preferably s=2; b<sub>0</sub>=0 or 1; A is the radical of a drug and is such as to meet the pharmacological tests reported in the description, C and C.sub.1 are two bivalent radicals. The precursors of the radicals B and B.sub.1 are such as to meet the pharmacological test reported in the description. A--(B).sub.b<sub>0</sub>--C--N(O).sub.s (I) ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:11937 USPATFULL  
TITLE: Pharmaceutical compounds  
INVENTOR(S): Del Soldato, Piero, Milan, ITALY  
PATENT ASSIGNEE(S): Nicox, S.A., Sophia Antipolis, FRANCE (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6987120	B1	20060117	
	WO 2000061541		20001019	<--
APPLICATION INFO.:	US 2001-926322		20000411	(9) <--
	WO 2000-EP3239		20000411	<--
			20011015	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	IT 1999-MI752	19990413
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Badio, Barbara P.	
LEGAL REPRESENTATIVE:	Arent Fox PLLC	
NUMBER OF CLAIMS:	3	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2070	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AI	20000411		
	20011015	PCT 371 date	
IT	50-44-2, 6-Mercaptopurine	51-21-8, Fluorouracil	53-79-2, Puromycin

54-25-1, 6-Azaauridine 57-22-7, Vincristine 59-05-2, Methotrexate  
 69-33-0, Tubercidin 84-16-2, Hexestrol 115-02-6, Azaserine  
 147-94-4, Cytarabine 148-82-3, Melphalan 154-42-7, Thioguanine  
 157-03-9, 6-Diazo-5-oxo-L-norleucine 302-79-4, Retinoic acid  
 305-03-3, Chlorambucil 320-67-2, Azacitidine 477-30-5, Demecolcine  
 488-41-5, Mitobronitol 576-68-1, Mannomustine 801-52-5, Porfiromycin  
 865-21-4, Vinblastine 1404-15-5, Nogalamycin 1853-37-8, Podophyllin  
 acid 2179-16-0, Ninopterin 2363-58-8, Epitriostanol 3094-09-5,  
 Doxifluridine 3733-81-1, Defosfamide 3930-19-6, Streptonigrin  
 4803-27-4, Anthramycin 5581-52-2, Thiamiprine 10318-26-0, Mitolactol  
 13665-88-8, Mopidamol 18378-89-7, Plicamycin 18883-66-4, Streptozocin  
 20830-81-3, Daunorubicin 21679-14-1, Fludarabine 22006-84-4,  
 Denopterin 22668-01-5, Etanidazole 24280-93-1, Mycophenolic acid  
 27778-66-1, Tenuazonic acid 29767-20-2, Teniposide 31698-14-3,  
 Ancitabine 33069-62-4, Paclitaxel 33419-42-0, Etoposide 50264-69-2,  
 Lonidamine 50935-04-1, Carubicin 52128-35-5, Trimetrexate  
 53643-48-4, Vindesine 53910-25-1, Pentostatin 54083-22-6, Zorubicin  
 54749-90-5, Chlorozotocin 55726-47-1, Enocitabine 56420-45-2,  
 Epirubicin 58957-92-9, Idarubicin 58970-76-6, Ubenimex 58994-96-0,  
 Ranimustine 65271-80-9, Mitoxantrone 65646-68-6, Fenretinide  
 66004-77-1 70052-12-9, Eflornithine 71486-22-1, Vinorelbine  
 71628-96-1, Menogaril 72496-41-4, Pirarubicin 72732-56-0, Piritrexim  
 80576-83-6, Edatrexate 82413-20-5, Droloxifene 84088-42-6, Roquinimex  
 87806-31-3, Porfimer sodium 90357-06-5, Bicalutamide 106486-76-4,  
 Carzinophilin 112887-68-0, Tomudex 114977-28-5, Docetaxel  
 123948-87-8, Topotecan 126595-07-1, Propagermanium  
 (antitumor; synthesis, activity and formulations of pharmaceutical  
 compds. for treatment of oxidative stress and/or endothelial  
 dysfunction)


IT 57-08-9,  $\alpha$ -Acetamidocaproic acid 33159-27-2, Ecabet  
 34675-84-8, Cetraxate 51481-61-9, Cimetidine 55028-70-1, Arbacloprostil  
 56695-59-3, Rosaprostol 57381-26-7, Irsogladine 59122-46-2,  
 Misoprostol 64204-55-3, Esaprazole 64218-02-6, Plaunotol  
 64506-49-6, Sofalcone 69900-72-7, Trimoprostil 70667-26-4  
 73121-56-9, Enprostil 73590-58-6, Omeprazole 77287-05-9, Rioprostil  
 92071-51-7, Rotraxate 102625-70-7, Pantoprazole  
 (antiulcer; synthesis, activity and formulations of pharmaceutical  
 compds. for treatment of oxidative stress and/or endothelial  
 dysfunction)

IT 302-79-4, Retinoic acid  
 (antitumor; synthesis, activity and formulations of pharmaceutical  
 compds. for treatment of oxidative stress and/or endothelial  
 dysfunction)

RN 302-79-4 USP/ATFLL

CN Retinoic acid (CA INDEX NAME)

Double bond geometry as shown.



IT 59122-46-2, Misoprostol


(antiulcer; synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction)

RN 59122-46-2 USPATFULL

CN Prost-13-en-1-oic acid, 11,16-dihydroxy-16-methyl-9-oxo-, methyl ester, (11a,13E)-(±)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



L6 ANSWER 9 OF 9 USPATFULL on STN  
ABSTRACT:

Compounds or their salts having general formulas (I) and (II): wherein s is an integer equal to 1 or 2, A is the radical of a drug that satisfies certain pharmacological tests, C and C.sub.1 are bivalent radicals, and precursors of the radicals B and B.sub.1 satisfy certain pharmacological tests.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:71127 USPATFULL

TITLE: Pharmaceutical compounds

INVENTOR(S): Del Soldato, Piero, Milan, ITALY

PATENT ASSIGNEE(S): Nicox S.A., Paris, FRANCE (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6869974	B1	20050322	
	WO 2000061537		20001019	<--
APPLICATION INFO.:	US 2001-926326		20011015	(9) <--
	WO 2000-EP3234		20000411	<--
			20011015	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	IT 1999-MI753	19990413
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Raymond, Richard L.	
LEGAL REPRESENTATIVE:	Arent Fox PLLC	
NUMBER OF CLAIMS:	7	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	2411	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AI

20000411

20011015 PCT 371 date

IT

50-33-9, Phenylbutazone, reactions 50-44-2, Mercaptopurine 50-59-9, Cephaloridine 50-91-9, Floxuridine 51-21-8, Fluorouracil 51-43-4, Epinephrine 51-45-6, Histamine, reactions 53-79-2, Puromycin 54-25-1, Azauridine 54-42-2, Idoxuridine 54-80-8, Pronethalol 54-85-3, Isoniazid 56-75-7, Chloramphenicol 56-81-5D, Glycerol, iodo-derivative 57-08-9,  $\alpha$ -Acetamidocaproic acid 57-22-7, Vincristine 57-27-2, Morphine, reactions 57-50-1, reactions 57-62-5 57-67-0, Sulfaguanidine 57-68-1, Sulfamethazine 57-92-1, Streptomycin, reactions 58-32-2, Dipyrindamole 59-05-2, Methotrexate 60-00-4, Edetic acid, reactions 60-54-8, Tetracycline 61-24-5, CephalosporinC 61-33-6, Benzylpenicillinic acid, reactions 61-68-7, Mefenamic acid 61-72-3, Cloxacillin 63-74-1, Sulfanilamide 65-45-2 65-49-6, p-Aminosalicylic acid 66-79-5, Oxacillin 68-26-8, Vitamin A 68-35-9, Sulfadiazine 68-41-7, Cycloserine 68-88-2, Hydroxyzine 68-90-6, Benziodarone 69-33-0, Tubercidin 70-00-8, Trifluridine 72-14-0, Sulfathiazole 74-31-7, N,N'-Diphenyl-p-phenylenediamine 74-55-5, Ethambutol 74-79-3, Arginine, reactions 76-41-5, Oxymorphone 76-42-6, Oxycodone 76-57-3, Codeine 76-58-4, Ethylmorphine 77-07-6, Levorphanol 79-57-2, Oxytetracycline 80-02-4, 2-p-Sulfanilylanilinoethanol 80-03-5, Acediasulfone 80-08-0, 4,4'-Sulfonyldianiline 80-32-0, Sulfachlorpyridazine 80-35-3, Sulfamethoxyypyridazine 80-53-5, Terpin 84-16-2, Hexestrol 87-08-1, Penicillin V 87-09-2, Penicillin O 87-28-5, Glycolsalicylate 89-45-2, Salicylsulfuric acid 90-05-1, Guaiacol 91-53-2, Ethoxyquin 93-14-1, Guaifenesin 94-10-0, Ethoxazene 94-19-9, Sulfathiodole 97-53-0, Eugenol 97-54-1, Isoeugenol 98-54-4 98-92-0, Nicotinamide 100-55-0, Nicotiny alcohol 101-91-7, 4'-Hydroxybutylanilide 103-12-8, Sulfamidochrysoidine 103-97-9, Phenocoll 110-17-8, Fumaric acid, reactions 111-17-1, 3,3'-Thiodipropionic acid 113-98-4, Penicillin G potassium salt 114-07-8, Erythromycin 115-02-6, Azaserine 115-68-4, Sulfadiazine 116-42-7, Sulfaproxyline 116-44-9, Sulfapyrazine 118-55-8, Phenyl salicylate 118-57-0, Acetaminosalol 119-98-2, Tocol 120-34-3, n-Sulfanilyl-3,4-xylamide 121-00-6, 3-tert-Butyl-4-hydroxyanisole 121-79-9, Propyl gallate 122-11-2, Sulfadimethoxine 125-28-0, Dihydrocodeine 125-29-1, Hydrocodone 127-07-1, Hydroxyurea 127-33-3, Demeclocycline 127-35-5, Phenazocine 127-69-5, Sulfisoxazole 127-71-9, Sulfabenzamide 127-79-7, Sulfamerazine 128-37-0, 3,5-Di-tert-Butyl-4-hydroxytoluene, reactions 128-46-1, Dihydrostreptomycin 129-20-4, Oxyphenbutazone 130-16-5, Cloxyquin 132-60-5, Cinchophen 132-92-3, Methicillinsodium salt 132-93-4, Phenethicillin potassium salt 133-11-9, Phenylaminosalicylate 134-55-4, Phenylacetylsalicylate 136-70-9, Protokylol 138-52-3, Salicin 143-52-2, Metopon 144-14-9, Anileridine 144-80-9, Sulfacetamide 144-82-1, Sulfamethizole 144-83-2, Sulfapyridine 147-94-4, Cytarabine 148-24-3, 8-Quinololinol, reactions 148-82-3, Melphalan 152-47-6, Sulfalene 153-61-7, Cephalothin 154-21-2, Lincomycin 154-42-7, Thioguanine 157-03-9, 6-Diazo-5-oxo-L-norleucine 299-42-3, Ephedrine 302-79-4, Retinoic acid 303-81-1, Novobiocin 305-03-3, Chlorambucil 315-30-0, Allopurinol 320-67-2, Azacitidine 322-79-2, Triflusal 339-43-5, Carbutamide 359-83-1, Pentazocine 389-08-2 390-64-7, Prenylamine 395-28-8, Isoxsuprine 404-86-4, Capsaicine 427-00-9, Desomorphine 437-74-1, Xanthinol niacinate 443-48-1, Metronidazole 447-41-6, Nyldrin 456-59-7, Cyclocladate 458-35-5 458-37-7, Curcumin 466-97-7, Normorphine 466-99-9, Hydromorphone 468-56-4, Hydroxypethidine 473-30-3,

Thiazolsulfone 477-30-5, Demecolcine 485-41-6, Sulfachrysoidine 486-79-3, Dipyrrocetyl 487-48-9, Salacetamide 488-41-5, Mitobronitol 495-76-1, Piperonyl alcohol 495-84-1, Salinazid 497-75-6 498-71-5, Sobrerol 501-94-0, 4-Hydroxyphenethyl alcohol 509-60-4, Dihydromorphine 515-49-1, Sulfathiourea 515-59-3, Sulfamethylthiazole 515-64-0, Sulfisomidine 515-69-5, Bisabolol 518-28-5, Podophyllotoxin 519-37-9, Etofylline 525-94-0, Penicillin N 526-08-9, Sulfaphenazole 526-84-1, Dihydroxymaleic acid 530-08-5, Isoetharine 530-75-6, Acetylsalicylsalicylic acid 530-78-9, Flufenamic acid 533-73-3, Hydroxyhydroquinone 536-24-3, Ethylnorepinephrine 539-08-2, p-Lactophenetic 545-90-4, Dimepheptanol 547-44-4, Sulfanilylurea 547-52-4, Sulfanilylsulfanilamide 547-53-5 551-27-9, Propicillin 552-94-3, Salsalate 553-69-5, Benzenemethanol, .a.-(1-(2-pyridinylamino)methyl)- 562-26-5, Phenoperidine 574-77-6, Papaveroline 576-68-1, Mannomustine 577-85-5, 3-Hydroxyflavone 581-64-6, Thionine 586-06-1, Metaproterenol 599-88-2, Sulfaperine 603-00-9, Proxiphylline 610-88-8 632-00-8, Sulfasomizole 635-65-4, Bilirubin, reactions 639-48-5, Nicomorphine 644-62-2, Meclofenamic acid 651-06-9, Sulfamer 652-37-9, Acefylline 723-46-6, Sulfamethoxazole 729-99-7, Sulfamoxole 751-97-3, Rolitetracycline 768-94-5, Amantadine 801-52-5, Porfiromycin 808-26-4, Sancycline 824-46-4, Methoxyhydroquinone 840-50-6, MADU 865-21-4, Vinblastine 959-10-4, Xenbucin 987-78-0, Citicoline 992-21-2, Lymecycline 1077-28-7, Thiocetic acid 1083-57-4, Bucetin 1110-80-1, Pipacycline 1159-93-9, Clobenzepam 1174-11-4, Xenazoic acid 1181-54-0, Clomocycline 1400-61-9, Nystatin 1403-66-3, Gentamicin 1404-04-2, Neomycin 1404-15-5, Nogalamycin 1406-18-4, Vitamin E 1503-53-3, 5-Bromosalicylic acid acetate 1531-12-0, Norlevorphanol 1553-60-2, Ibufenac 1596-63-0, Quinacillin 1614-20-6, Nifurpazine 1695-77-8, Spectinomycin 1853-37-8, Podophyllic acid 1926-49-4, Clometocillin 1953-02-2, Tiopronin 1984-94-7, Sulfasymazine 2013-58-3, Meclocycline 2016-63-9, Bamifylline 2030-63-9, Clofazimine 2055-44-9, Perisoxal 2179-16-0, Ninopterin 2315-08-4, Salazosulfadimidine 2316-64-5, Bromosaligenin 2363-58-8, Epitiostanol 2373-80-0, 3,4-Methylenedioxybenzoic acid 2447-57-6, Sulfadoxine

(drug precursor)

IT 52-90-4, L-Cysteine, reactions 53-86-1, Indomethacin 89-57-6, Mesalamine 103-90-2, Paracetamol 321-64-2, Tacrine 18683-91-5, Ambroxol 59122-46-2, Misoprostol 66376-36-1, Alendronic acid 73590-58-6, Omeprazole 164790-49-2

(synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction)


IT 302-79-4, Retinoic acid

(drug precursor)

RN 302-79-4 USPATFULL


CN Retinoic acid (CA INDEX NAME)

Double bond geometry as shown.



IT 59122-46-2, Misoprostol  
 (synthesis, activity and formulations of pharmaceutical compds. for  
 treatment of oxidative stress and/or endothelial dysfunction)  
 RN 59122-46-2 USPATFULL  
 CN Prost-13-en-1-oic acid, 11,16-dihydroxy-16-methyl-9-oxo-, methyl ester,  
 (11*a*,13*E*)-(±)- (CA INDEX NAME)

Relative stereochemistry.  
 Double bond geometry as shown.



=> FIL STNGUIDE  
 COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FULL ESTIMATED COST

66.02	85.97
-------	-------

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION

CA SUBSCRIBER PRICE

-4.80	-4.80
-------	-------

FILE 'STNGUIDE' ENTERED AT 12:22:00 ON 06 JUN 2008  
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.  
 LAST RELOADED: May 30, 2008 (20080530/UP)